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Abstract 
Endothelial cells form the inner lining of blood and lymphatic vessels. 
In mice only tumours of the blood vessel endothelium (haemangiomas) 
have been thus far reported. In the first part of this thesis is described a 
highly reproducible method for the induction of benign tumours of the 
lymphatic endothelial cells (lymphangioma) in mice, by intraperitoneal 
injection of incomplete Freund's adjuvant. Different criteria have been used 
in order to establish the nature of the induced lesion. Morphological and 
histophatological studies of the tumour developed in the peritoneal cavity 
revealed the presence of cells at various levels of vascular development. 
Expression of the endothelial markers PECAM/CD31, ICAM-l/CD54, ICAM 
2/CDI02 as well as the vascular endothelial growth factor (VEGF) receptor 
Flk-I, the endothelial cell specific receptors Tie-I, Tie-2, and the lymphatic 
endothelial specific Flt-4 was identified. When the lesion was induced in ~-
galactosidase knock-in Flt-4 +/- mice, the tumour endothelia could be stained 
blue in a number of tumour cells. Tumour-derived cells were propagated in 
vitro where they spontaneously differentiated, forming vessel-like structures. 
This evidence leads to the conclusion that this is the first experimental 
protocol for the induction of a lymphatic endothelium hyperplasia in mice 
peritoneum. 
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The second part of this thesis describes the use of this model system to 
investigate the profile of chemokine expression in murine lymphangiomas 
and in lymphangioma-derived lymphatic endothelial primary cultures. 
Chemokines are a superfamily of small, secreted chemoattractant molecules 
that plays a key role in the immune cell trafficking. Although production of 
chemokines by vascular endothelial cells has been extensively documented, 
there is much less information regarding the lymphatic endothelium. The 
reported results are the first detailed analysis of chemokine production by 
lymphatic endothelial cells. Chemokines belonging to all three subfamilies 
(CXC, CC and C), were found to be 
expressed in lymphangioma. Among these molecules is remarkable the 
identification of CIO, a molecule previously identified only in the bone 
marrow. 
The molecular as well as functional assays performed provide an indication 
of the signals that mediate the recruitment of leukocytes into lymphatic 
vessels. 
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Chapter 1 
INTRODUCTION 
The vascular and the lymphatic systems are dispersed organs evolved 
to provide specific functions such as oxygenation and nutrition to cells 
throughout the body and the transport of cells necessary to mediate host 
defence against infections. The lymphatic system, in particular, is also 
involved in drainage activity of fluids, macromolecules and cells that have 
leaked into the interstitium. These parallel systems playa significant role in 
the life of an organism and homeostasis maintenance and consequently are 
subjects of interest for many investigations. Despite the important 
anatomical and functional differences between vascular and lymphatic 
vessels there is a common, central element in both systems: the endothelial 
cells. 
The present thesis is focused on the study of the characterization of 
lymphatic endothelial cells deriving from tumoral masses induced by 
intraperitoneal treatment of mice with Freund's adjuvant. This lesion shows 
the characteristics of lymphangioma as described in humans and is the first 
report of this kind of tumor in mouse. For this reason it represents a 
convenient model to investigate the hypothesis that lymphatic endothelial 
cells produce chemokines which may account for the trafficking and 
recruitment of leukocytes into the lymphatics. 
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1.1 The embryonic origin 
Vasculogenesis: 
The cardiovascular system is the first functional organ system that 
develops in the vertebrate embryo. Embryonic growth and differentiation 
essentially depends on transport of nutrients and waste through the early 
vasculature, and certain events in morphogenesis are thought to be 
influenced by hemodynamic forces of the beating heart. 
The first step in blood vessels formation is the differentiation of 
vascular endothelial cells, which later on cover the entire inner surface of all 
blood vessels. During the process of gastrulation, embryonic epithelium 
(also called inner cell mass in the murine embryo), invaginates through the 
primitive streak. During this process mesodermal cells are induced by 
members of the fibroblast growth factor (FGF) family and migrate widely 
throughout the extraembryonic membranes and the embryo proper (7, 56). 
At this stage, during murine embryogenesis, angioblasts arise from 
the differentiation of mesodermal cells. Angioblast is defined as a cell type 
that has the potency of differentiating into a endothelial cell but has not yet 
acquired all the characteristic markers and has not yet formed a lumen. 
Angioblasts can be first detected in the embryo as early as stage E7.0, and 
within the yolk sac extraembryonic mesoderm between E7.5 and E8.5 (54, 
245)(Fig.l). 
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Figure 1. Origin of endothelial cells. 
a) Schematic view of mesoderm differentiation and migration in a 
gastrulating chick embryo after about 17 hrs of incubation. The 
stippled area indicates the area vasculosa. 
b) Schematic cross section of a blood island in the area opaca (AO) 
and angioblast in the area pellucid a (AP) of a 24hrs old chick 
embryo. 
Angioblast are precursors of endothelial and haemopoietic cells. 
Forming the blood islands haemopoietc precursors are in the internal 
part, surrounded from endothelial cells precursors. 
Reproduction from: Differentiation of endothelium. W. Risau FASEB J. 9,296-933 
(1995) 
The first intraembryonic angioblasts are seen at the one-somite stage 
within paraxial and lateral plate mesoderm in close contact with the 
endoderm (54). From here, angioblastic strands are formed along the lateral 
edges of the somites, which represents the primordia of the dorsal aorta. 
Very shortly after the intraembryonic counterparts have appeared, 
blood islands emerge in the yolk sac from the splanchnopleuric mesoderm 
of the area opaca. The peripheral cells of these aggregates are angioblasts 
(130), whereas the cells in the center of the blood islands are hemopoietic 
precursor cells. 
The formation of these blood islands from in situ differentiating 
endothelial cells is called vasculogenesis. The subsequent processes of blood 
islands fusion and formation of lumina by angioblasts leads to a primordial 
vascular network that extends by sprouting of new capillaries 
(angiogenesis), resulting in an elongated, highly branched vascular plexus. 
Already at the 2-somite stage the interconnection between this 
extraembryonic plexus and the intraembryonic vascular primordia is 
established. 
There is a substantial difference between extraembryonic and 
intraembryonic vasculogenesis process. In the area opaca (yolk sac), 
endothelial cells differentiation occurs at the same time and in close 
association with hemopoietic precursors in the blood islands. 
The close association of haematopoietic and endothelial precursors 
cells has led to the assumption that endothelial cells and haematopoietic cells 
may have a common precursor called haemangioblast. This hypothesis is 
supported by the observations that several molecules (e.g. CD34, PECAM-
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1/CD31, Angiotensin converting enzyme (ACE), von Willebrand Factors 
(vWF), and P-selectinl CD62P), are expressed by both cell lineages. 
However, within the embryo (zona pellucida), endothelial cells 
differentiate from the mesoderm as solitary angioblasts without the 
concomitant differentiation of haemopoietic cells, except for a small region of 
the aorta (para aortic clusters)(55). In a second phase, angioblasts migrate and 
fuse with other angioblasts and capillaries or form vessels in situ. This 
angioblasts differentiation from mesodermal precursors (vasculogenesis) is 
identified also within organs of endodermal origin (lung, pancreas, spleen), 
whereas organs of ectodermal or mesenchymal origin (brain, kidney) seem 
to be vascularized by sprouting of new capillaries from the pre-existing 
network (226, 252). At this stage, these primitive blood vessels are populated 
by haemopoietic cells derived from the yolk sac or the paraaortic cluster, 
while the definitive haematopoietic organs are colonized only by 
haemopoietic stern cell derived from the paraaortic region. 
The process of blood islands induction and subsequent blood vessels 
formation, therefore can be summarized with the following steps (308, 188): 
• contact of either migrating, gastrulating or polyingressing cells 
bearing growth factor-receptors with growth factor producing cells; 
• activation and signal transduction of the growth factor-receptors 
leading to the activation of genes; 
• aggregation of mesodermal cells adjacent to the endoderm 
(splanchnopleuric or visceral endoderm); 
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• differentiation of angioblasts (area pellucid a) or angioblasts and 
haemopoietic cells (area opaca and paraaortic clusters) either as a 
common precursor (haemangioblast) or as two lineages; 
• differentiation of endothelial cells, lumen formation, and basal 
lamina production; 
• further growth and migration of endothelial cells and connection of 
blood islands leading to a primary capillary plexus. 
Angiogenesis: 
After the primary vascular plexus is formed, more endothelial cells are 
generated, which can form new capillaries by sprouting or by splitting from 
their vessel of origin in a process termed angiogenesis. Angiogenesis is the 
predominant mechanism of blood vessels formation in later stages of 
embryonic development and in the adult (94), and plays an important role in 
the remodelling of the primary capillary network into a mature vascular 
system consisting of vessels of different diameter and functions. 
There are at least two mechanisms of angiogenesis : 
• true sprouting of capillaries from pre-existing vessels, 
• non-sprouting angiogenesis or intussusception. 
Sprouting angiogenesis occurs both in the yolk sac and in the embryo (most 
frequently during later organogenesis, particularly in the brain). There is a 
proteolytic degradation of the extracellular matrix that is followed by 
chemotactic migration and proliferation of endothelial cells (232, 244). 
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Sprouts bearing long filopodia at their tips are then formed which extend 
from the endothelial lining. Two opposite pre-existing capillaries, meet each 
other and form a solid strand splitting the intervascular space. 
In the process of intussusception, a solid mesenchymal pillar grows 
into a capillary, subsequently enlarges and forms a new intervascular space. 
Non-sprouting angiogenesis predominates in organs like lungs that contain 
intrinsic endothelial precursors and is initially vascularized by vasculogenesis 
(89,263) (Fig. 2). 
During all the embryological life the vascular system is rapidly 
remodelled not only to provide the nourishment of the fast-growing 
embryo, but also to mature in response to specific demands of the 
developing organs and tissues. Remodelling is initiated by circulating factors 
and other signals such as shear stress and hyperoxia that are transduced by 
endothelial cells (240). Modification of the extracellular matrix, secretion of 
factors with stimulating or inhibiting effects, modification of the expression 
pattern of specific receptors or adhesion molecules, differentiation of 
neighbouring cells, lead to the differentiation of angioblast to the quiescent, 
organ specific and established endothelium of the adult. 
In the past decade there has been a significant advance in the 
understanding of molecular mechanisms regulating vasculogenesis and 
angiogenesis in the embryo and new blood vessels formation during 
physiological and pathological processes in the adult. 
For these processes growth factors and their receptors play an 
important role. 
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Before to approach the molecular mechanisms that underlie these 
processes, it will be important to summarize as follow: 
The term "vasculogenesis" refers to the earliest stage of vascular development, in 
which vascular endothelial cell precursors undergo differentiation, expansion, and 
coalescence to form a network of primitive tubules: the primary capillary plexus. 
Angiogenesis is the process by which, in later stages of embryo development, the 
primary plexus is remodelled and involves sprouting, branching and differential 
growth of blood vessels to form the more mature appearing vascular patterns seen 
in the adult organism. In the adult, all the vascular modifications occur by 
angiogenesis. 
9 
1.2 Molecular mechanisms of Vasculogenesis and Angiogenesis 
The molecular mechanisms that underlie vasculogenesis and 
angiogenesis are still not completely understood, but recently some progress 
has been made, mainly due to the identification of molecules that are 
specifically expressed in endothelial cells as soon as they differentiate from 
the mesoderm. The expression of some of these molecules was investigated 
in order to define the endothelial origin of the lesion induced in our 
experimental model. 
Fibroblast growth factors 
Many evidence (89, 109, 151), support the idea that generation of 
angioblasts from mesoderm is due to the presence of members of the 
fibroblast growth factor (FGF) family. 
Fibroblast growth factors are a family of nine structurally related 
polypeptides that are mitogenic for a broad range of cell types as well as 
mediators of a wide spectrum of developmental and pathophysiological 
processes in vivo and in vitro (39,40). 
The binding of basic-FGF to fibroblast growth factor receptor-1 
(FGFR1) that is expressed on the mesodermal cells surfaces, lead to Ras and 
MAP kinase activation which phosphorylates transcription factors (TF) 
resulting in activation of genes necessary for the FGF response (98). After 
induction by FGF and the consequent proliferation induction of target cells, 
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Figure 2. Vasculogenesis and Angiogenesis. 
Schematic representation of vascular development. The processes (red labels), 
molecules (green labels) and appearances (black labels) involved in vascular 
development. Red tips in the primary capillary plexus represent sprouts, 
yellow circles represent splitting pillars. The haemangioblast as a bipotential 
precursor is still hypothetical and intermediate steps between some processes 
have been omitted. Remodelling and maturation is dependent on the tissue 
and organ context. It is schematized here from the observation in the avian 
yolk-sac vascular system. A, arteriole, V, venule, SMC, smooh muscle cells, 
Pcf, pericytes. None of the figure is drawn to scale. 
Reproduction from: Mechanism of angiogenesis. W. Risau .Nature, 386,671-674 (1997) 
the first molecule known to be expressed in a population of mesodermal 
cells giving rise to angioblast is the Vascular Endothelial Growth Factor 
Receptor-2 (VEGFR2) or Fetal Liver Kinase-1 (Flk-1) (193,315). 
In contrast to the crucial function of FGFs and FGF-receptors m 
mesoderm induction, these molecules do not play a major role in the 
subsequent morphogenesis of the vascular system in the embryo. In the 
adult, endothelial cells of larger vessels express FGF-receptors and respond 
to FGF in vivo suggesting that FGF is probably relevant for regenerative 
processes but not for vasculogenesis and angiogenesis (174). 
Vascular Endothelial Growth Factors and 
related Endothelial-specific Receptor Tyrosine Kinases 
Vascular Endothelial Growth Factors constitute a family of secreted 
glycoproteins that have so far been considered as the only growth factors 
relatively specific for endothelial cells. Almost 10 years ago it was identified 
VEGF (or Vascular Permeability Factor), the first member of this family (147, 
171), a homodimeric glycosylated protein that exists in four isoforms of 121, 
165, 189 and 206 amino acids (227). At present four other proteins, placental 
growth factor (181), VEGF-B (215},VEGF-C (139) and VEGF-D (I), form the 
endothelial specific family of related growth factors with structural 
homology to platelet-derived growth factor (PDGF). In particular the 
cysteines building up the structural fold of these dimeric proteins (three 
intramolecular disulfide bridges and two intermolecular bridges cross-
linking the polypeptide chains) are conserved for these growth factors. 
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• VEGF is the most critical regulator of endothelial cell proliferation, 
migration and permeability during embryonic vasculogenesis and, in the 
adult, in physiological and pathological angiogenesis (78, 87,284). 
VEGF expression by the endodermal germ layer was identified at E7.5 
day of the mouse embryogenesis, and was demonstrated that its paracrine 
secretion supports the differentiation of the VEGFR-2 expressing 
mesodermal cells to angioblasts (34). It was also reported that a threshold 
concentration of VEGF is necessary to sustain VEGFR-2 expression: in cells 
not receiving sufficient signals, a down regulation of the receptor and a lack 
of differentiation of endothelial cells initially expressing VEGFR2 were 
described. Finally, mice heterozygous for the VEGF gene disruption die by 
embryonic day 10.5 or 11.5, indicating a critical dose-dependent embryonic 
requirement for this growth factor (44, 86) (Table I). 
VEGF acts by stimulating members of a family of largely endothelial-
specific receptor tyrosine kinases that includes fms-like tyrosine kinase 1 
gene (Flt-l}/vascular endothelial growth factor receptor-l (VEGFR-l) and 
fetal liver kinase gene-l (Flk-l)/ vascular endothelial growth factor receptor-
2 (VEGFR-2) (64,238, 298) More recently a third receptor homologous to FIt-
1 and Flk-l, designated Flt-4 (VEGFR-3), was identified. It had been 
previously described as an orphan receptor because it was shown not to 
bind VEGF (203, 224), while at present it is known to be the specific receptor 
for VEGF-C (Vascular endothelial Growth Factor-C, or VEGF related 
protein). The FLT gene family belongs to the class III RTKs (286), which also 
includes the (l and ~ chains of platelet-derived growth factor receptors 
(PDGFR), the product of the FLT3/FLK2 gene and two protooncogenes (c-
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fms and c-kit). The c-.fms protooncogene was isolated from the feline sarcoma 
virus. The Flt-4, Flt-I and Flk-I RTKs differ from the others members of class 
III RTKs by having seven instead of five Ig-like loops in their extracellular 
domains (Fig. 3). 
-As previously mentioned, Flk-I is the first receptor that appears in 
angioblasts, already detectable in presumptive mesodermal yolk-sac blood 
island progenitors as early as E7.0 day. During the embryological 
differentiation Flk-1 become restricted to the endothelial lineage, while at 
this stage marks both endothelial and haemopoietic precursors cells (193). 
Mice lacking Flk-1, indeed, die in utero between 8.5 and 9.5 days p.c., as a 
result of an early defect in the development of hemopoietic and endothelial 
cells (261). This data indicate that Flk-1 is essential for yolk-sac blood island 
formation and vasculogenesis in the mouse embryo (Table.l). 
-Also the expression of the other receptor for VEGF, Flt-I, was 
detected during mouse embryogenesis in populations of embryonic cells 
from which endothelium is derived (230), but the data obtained from mice 
lacking Flt-l indicate a role different from the one described for Flk-l. Mouse 
embryos homozygous for targeted mutation in the flt-l locus, form 
endothelial cells in both embryonic and extraembryonic regions, but these 
cells are assembled into abnormal disorganized vascular channels, and the 
animals die in utero at mid-somite stage. Thus, it seems that the Flt-1 
signalling pathway is important in controlling normal cells adhesion between 
endothelial progenitor cells, and/or regulating the interaction of endothelial 
cells with the extracellular matrix (95) (Table I). 
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• During the early stages of mouse embryological development also 
the mRNA expression of the third endothelial-specific receptor, the product 
of fms-like tyrosine kinase 4 gene (Flt-4), become detectable (140). 
In the past years many investigations were performed in order to 
improve characterisation of this receptor from the biochemical point of view, 
but its function became evident only when the ligand was identified. 
The analysis of RNA isolated from several human and mouse sources 
showed that Flt-4 is expressed as transcripts of 4.5 and 5.8 kb generated by 
alternative polyadenylation and alternative splicing, but only the protein 
translated from the longest form was identified in tissues (223). The two 
putative Flt-4 forms differ for the presence of an extended carboxy terminal 
tail of 65 amino acid residues. This tail is probably significant for the protein 
function because it contains three additional tyrosyl residues that in other 
receptor tyrosine kinases have been shown to provide autophosphorylation 
sites important for substrate binding. The Flt-4 precursor is a protein of 170 
kDa which upon complete glycosylation becomes a polypeptide of 190 kDa. 
This is one of the mature forms of Flt-4, a transmembrane protein with 
seven immunoglobulin like extracellular domains and a intracellular tyrosine 
kinase domain (Fig. 3). A second form representing the major component, is 
also found and is composed of two chains of 120 kDa and 75kDa deriving 
from proteolytic cleavage of the highly glycosylated 190 kDa precursor, 
linked together by a disulfide bond. 
Finally, the activated Flt-4 tyrosine kinase domain was found to 
interact with the Src homology 2 domains of the SHe and GRB2 adaptor 
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proteins in vitro and with SHC in cells suggesting that the endothelial cell Flt-
4 receptor has a functional tyrosine kinase domain (224). 
Flt-4, as above mentioned, is a tyrosine kinase receptor related to the 
VEGF receptors Fl~-l and Flk-1/KDR, but the observations that VEGF does 
not show specific binding to Flt-4 nor induce its autophosporylation (203, 
224) and that the expression pattern differs from the one of Flt-l and Flk-l, 
suggest distinct functions in the regulation of the growth/differentiation of 
the endothelial network (140). 
At E8.5 of mouse development Flt-4 expression is described in the 
angioblast of head mesenchyme, in the cardinal vein and extraembryonally 
in the allantois. At 12.5 day p.c. embryos the Flt-4 mRNA signal is detected in 
developing venous and presumptive lymphatic endothelia, while arterial 
endothelia become negative. This finding suggests that Flt-4 is a receptor 
involved in lymphatic vessels development. This hypothesis is supported by 
the finding that during later stages of development Flt-4 become absolutely 
restricted to vascular plexuses devoid of red cells, representing developing 
lymphatic vessels. Although Flt-4 is restricted largely to lymphatic 
endothelium, mice that contain a knockout of the gene for VEGFR-3 display 
early embryonic mortality due to the defects in the organization of large 
vessels prior to the emergence of lymphatics (73) (Table I). 
• The expression pattern of Flt-4 suggest that VEGF-C, a member of 
VEGFs family able to bind and phosphorylate in vitro Flk-l and Flt-4 (139, 
158), may function in the formation of the venous and lymphatic vascular 
system during the embryogenesis. Constitutive expression of VEGF-C in 
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adult tissues suggests that this molecule is also involved in the maintenance 
of the differentiated functions of the lymphatic endothelium where Flt-4 is 
expressed (140). Furthermore, while VEGF-C is homologous to other 
members of the VEGF/platelet derived growth factor (PDGF) family, its C-
terminal half contains extra cysteine-rich motifs reminiscent of the BR3P 
sequence (69) and characteristic of a protein component of silk produced by 
the larval salivary glands of the midge, Chironomus tentans. Lymphatic 
capillaries do not have well formed basal laminae and an interesting 
possibility remains that the VEGF-C silk-like BR3P motif is involved in 
producing a supra molecular structure which could regulate the availability of 
the growth factors in tissues (139). 
The suggested function of Flt-4 and its ligand VEGF-C was confirmed 
by the observation that transgenic mice carrying human VEGF-C develop a 
hyperplasia of the superficial lymphatic network due to the specific over 
expression of the growth factor. VEGF-C is also a ligand for Flk-1, but the 
functional significance of this potential interaction in vivo is unknown, and in 
the above transgenic mice it does not induce the sprouting of new vessel 
(137). From these evidences it seems that VEGF-C induces specific lymphatic 
endothelial differentiation and proliferation. At present it is not reported the 
description of an animal model knockout for the VEGF-C gene. Its receptor 
Flt-4 is so far the only lymphatic-restricted marker described. 
• Recently (1), by computer-based homology searching, VEGF-D a 
new member of the VEGF family was identified. This new growth factor is 
closely related to VEGF-C, and the analyses of VEGF-D receptor specificity 
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revealed that also VEGF-D is a ligand for Flt-4 and Flk-l. Although VEGF-D 
is mitogenic for endothelial cells in vitro, its in vivo function is still unknown. 
Because the receptor binding specificities of VEGF-D and VEGF-C are 
similar, it is possible that also VEGF-D could be involved in the regulation of 
the growth and/ or differentiation of lymphatic endothelium. 
A wide view of the role of Vascular Endothelium Growth Factors and 
related receptors could be summarized as follow: 
Flk-l and Flt-4 are widely expressed during the first stages of 
embryonic development in endothelial cells. Later, in the fetus, Flt-4 
becomes confined to lymphatic endothelial cells (LECs), while Flk-l is 
expressed in the vascular counterparts. Because the mature forms of both 
VEGF-C and VEGF-D can activate these receptors, these growth factors 
could play roles in coordinating the development of vascular and lymphatic 
endothelia. It is conceivable that VEGF-C and VEGF-D could serve at a 
particular site in an embryo to support the growth of both vascular and 
lymphatic endothelia, whereas expression of VEGF, that activates Flk-l and 
Flt-l but not Flt-4, would playa critical role in the angioblasts commitment 
and attract the growth of vascular endothelium. Thus changes in the levels of 
the expression of the genes for VEGF family members could serve to 
modulate the abundance of different types of vessels in tissue. 
Angiopoietin and related receptors 
Vascular endothelial growth factor receptors are tyrosine kinase 
receptors that structurally belong to the PDGF receptors subclasses III, while 
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FGF receptors form the subclass IV. Both of these subclasses are 
characterized by extracellular units stabilized by intra-chain disulfide bonds 
(immunoglobulin like folds). TIE-I and TIE-2 (also called Tunica intern a 
endothelial cell kinase, TEK), because of their extracellular domains that 
contain three different types of structural motifs (immunoglobulin (I g)-like 
loops, cysteine-rich epidermal growth factor (EGF)-like repeats and 
fibronectin type III (FNllI) repeats), form a different receptor tyrosine kinase 
receptor subfamily (72, 228) involved in vascular development (75, 155) (Fig. 
3). 
Indeed, the onset of embryonic expression for these receptors seems 
to follow that of the VEGF receptors (71), and the recent generation of mice 
lacking either TIE-lor TIE-2 has confirmed the critical requirement of these 
receptors during blood vessel formation (253). Embryos deficient in TIE-l 
expression failed to establish structural integrity of vascular endothelial cells, 
resulting in oedema and subsequently localized haemorrhage. Mice lacking 
TIE-1, die between E13.5 and P.O. (Table I). 
• Moreover, embryos lacking TIE-2 are more severely affected and 
die between E9.5 and E10. (Table I). Close observation of TIE-2 deficient mice 
revealed a malformation of vascular network: in the head region at E9.5, 
vessels were uniformly dilated and there was no clear distinction between 
larger and smaller vessels as seen in wild-type embryos, in neuroectoderm 
the presence of capillary sprouts was not detectable and the vessels that 
form the myocardial circulation failed to form extensive branches. In the 
extra-embryonic yolk-sac vasodilatation and abnormal vascular network 
formation was also observed. 
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The phenotypic differences between these embryos suggest distinct 
roles of these two receptors. TIE-l function is related to endothelial 
differentiation and the establishment of blood vessel integrity, while TIE-2 is 
probably involved in the angiogenic processes. 
Interestingly, in humans, a missense mutation resulting in an arginine-
to-tryptophan substitution at position 849 in the kinase domain of the 
receptor tyrosine kinase TIE-2 was reported in two disparate families with 
venous malformations (294). This mutation results in increased activity of 
TIE-2 and the phenotype originated by the activating mutation in TIE-2 is 
comprised of vein-like lumens lined by a monolayer of endothelial cells, but 
with thin walls in which smooth muscle layers are markedly reduced, as 
compared to normal vessels with similar sized lumens. This observation 
suggested that TIE-2 receptor expression by endothelial cells is coupled, by 
some as yet unknown mechanism, to chemotaxis and proliferation of 
mesenchymal cells and differentiation into smooth muscle cells. 
• The recent identification of the specific ligand of TIE-2, termed 
Angiopoietin-l, allows to elucidate the role of this receptor. Angiopoietin-l is 
a secreted 70kDa glycoprotein of 498 highly conserved amino acid residues, 
which, with a KD =3.7 nM, binds and activates TIE-2 (60). The addition of this 
ligand to endothelial cell culture does not show either induction of cells 
proliferation nor capillaries formation as previously described for VEGF and 
other classic endothelial growth factors. This observation suggest that in vivo 
the Angiopoietin-l binding to TIE-2 plays a critical role during angiogenesis 
regulating the interaction of endothelial cells with the surrounding 
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mesenchymal cells and the extracellular matrix. This suggestion was 
confirmed by the observation that loss of Angiopoietin-l expression in 
deficient mice leads, in a less severe way, to the same defects described in 
mice lacking TIE-2 (277) (Table I). Ultrastructural analyses demonstrated the 
failure to recruit smooth muscle cells and pericyte precursor and the poor 
association with the underlying matrix. These are probably the major cause 
in the inhibition of the appropriate vessels stabilization and maturation. 
• The vasculature malformations detected in mice due to TIE-2 or 
angiopoietin-l deficiency are extremely similar to the ones observed in mice 
lacking tissue factor (TF), Platelet-derived growth factor receptor-~ (PDGFR-
~) and TGF-~ (44, 172,246). In these animal models it was reported improper 
interaction between endothelial and pericytes cells and absence of smooth 
muscle cells differentiation (Table I). All these data lead to the following 
general interpretation: the Angiopoietin-l/TIE-2 system plays an important 
role in vasculature development that differs from the one described for 
VEGFs and related receptors because it becomes evident in later stages of 
mouse embryogenesis and does not affect endothelial cells proliferation. 
Angiopoietin-l produced by mesenchymal cells activates the TIE-2 receptor 
on endothelial cells, which in tum leads to the production and/or release of a 
recruiting signal for mesenchymal cells. Once mesenchymal cells arrive and 
contact endothelium, TGF-~ may be activated (10) and induce differentiation 
of the mesenchymal cells into pericytes and smooth muscle cells, inhibit 
endothelial cells proliferation and stimulate matrix deposition. Because TGF-
~ induces matrix production and modulate integrin expression, an absence of 
endothelial-smooth muscle cell contacts, with the resulting lack of TGF-
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~, may also explain the poor vascular integrity and the reduced remodelling 
observed in the TIE-2 receptor/ angiopoietin-l-null mice. 
Eph receptors and related Ephrin ligands 
The Eph receptors comprise the largest subfamily of RTKs, including 
at least distinct 14 members. The Eph receptors are divergent in sequence 
from other RTKs and are closely related to cytoplasmic tyrosine kinases 
within their kinase domains (120) (Fig. 3). All the Eph receptors were initially 
isolated as orphan receptors, lacking known ligands, but over the past five 
years at least eight Eph receptor ligands (ephrins) have been described. The 
ephrins, like their receptor counterparts, are also rather unique among RTK 
ligands. 
The ephrin-Eph system functions in cell-to-cell rather than long range 
communications, because are attached to the plasma membrane (61, 220). 
Membrane attachment seems to promote clustering or multimerization of 
the ligands and it is this clustering that seems to be necessary to activate 
receptors on adjacent cells (61). Ephrins are divided into two subclasses: the 
five members of the ephrin-A subgroup (ephrinA1-AS) are attached to the 
outer leaflet of the plasma membrane via a glycosylphosphatidylinositol 
(GPI)-anchor, whereas ephrinB ligands (ephrins B1-B3) present a 
transmembrane region followed by a conserved cytoplasmic domain. Ephrin 
A and ephrinB molecules bind specifically the corresponding EpM and EphB 
receptor subfamilies respectively whereas, within these subfamilies, 
interactions are highly promiscuous (32, 100). 
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Figure 3. Ligands and RTK families involved in vascular development. 
A) VEGFS and the VEGF receptors. 
B) The angiopoietins (Ang) and the TIe receptor family. 
C) The ephrins and the Eph receptors. 
Arrow indicate documented interactions among ligands with their receptors. 
Receptors and ligand structures are drawn colour coded to indicate their domains 
of expression; purple represents proteins found expressed on both arteries and 
veins. Red and blue structures are found on arteries and veins, respectively; yellow 
denotes expression on lymphatic vessel and green structures represents receptors 
or ligands expressed in tissue surrounding blood vessels. 
These receptors and their cell-surface-bound ligands, play an 
important roles in a variety of processes during embryonic development of 
mammals, lower vertebrate and invertebrates and have been most studied 
for their role in the nervous system (48, 99, 219, 90). Most recently, 
expression studies and development of knockout animal models establish 
that ephrins and Eph family members are key players not only in the 
process of vascular development, but also in vascular remodelling 
(angiogenesis) (91, 133,2, 135, 189,299,316). 
During embryonic development, the first step of blood vessels 
formation involves the differentiation of primitive mesodermal cells into 
vascular endothelial cells, which will line the internal surface of all vessels. 
The vertebrate circulatory system is composed of arteries and veins: arterial 
and venous endothelial cells are molecularly distinct from the earliest stages 
of angiogenesis. This distinction is revealed by expression on arterial cells of 
ephrin-B2 (21, 22), whose cognate receptor Eph-B4 (8) is expressed on 
venous cells as demonstrated following the expression of ephrin-B2-LacZ 
gene (299). Ephrin-B2 knockout mice display defects in angiogenesis by both 
arteries and veins in the capillary networks of the head and yolk sac as well 
as in myocardial trabeculation: the deficient mouse dies in E10.5 (Table I). 
These data are suggesting that differences between arteries and veins are in 
part genetically determined and reciprocal interactions between pre-specified 
arterial and venous endothelial cells are crucial for the morphogenesis of the 
capillary bed and angiogenesis mechanism (299,316). In mice lacking ephrin-
B2 was also observed that yolk mesenchymal and peri-endothelial cells 
appeared to be poorly associated with the endothelium. Defects in later 
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vascular remodelling as well as in heart trabeculation, due to the altered interactions 
of endothelial cells with support cells, was highly reminiscent of defects observed in 
mice lacking Angl or its receptor Tie2 (253,277). 
Recently was also found that other B-class receptors and ligands displayed 
expression patterns overlapping those of ephrin-2 and EphB4 and play critical roles 
in vascular development (2). Embryos lacking both EphB2 and Eph3 (EphB2/EphB3) 
with a penetrance of 30%, exhibited defects in vascular development that largely 
phenocopy those of the ephrin-B2 knockouts: defects in the primary plexi of the yolk 
sac and head and defective heart morphogenesis but with a normal sprouting 
angiogenesis. Ephrin-Bl is co-expressed with ephrin-B2, on arterial endothelium, 
though its presence there is not sufficient to compensate for the knockout of ephrin-
B2 (2), and also expressed in veins. At present the EphB4 knockout model is not 
officially described, but a personal communication of M. Aguet to N.W. Gale (101), 
reported that mice lacking EphB4 display embryonic lethal phenotype, probably due 
to vascular defects in angiogenesis. At present also the ephrin-Bl knockout mice is 
not available. 
Gene knockout Tirneof Stage of vessel Causes of mortality References Death Development 
Reduced red blood cells; 
defective heart and Carmaliet et al. 
VEGF-A( + / -) E11.5 Vasculogenesis/ aorta formation; (1996); Ferrara (Angiogenesis ) defective vessel 
et al. (1996). 
connectivity; defective 
sprouting. 
Absent dorsal aorta; Carmaliet et al. 
VEGF-A( -/ -) E10.5 Vasculogenesis defective endothelial (1996); Ferrara 
cell development. et al. (1996). 
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VEGFR-1 E8.5-E9.5 Vasculogenesis Failure of endothelial Fong et a1. 
cell formation. (1995). 
Excess endothelial cells 
VEGFR-2 E8.5-E9.5 Vasculogenesis form abnormal vessels Shalaby et a1. 
structures entering (1995, 1997). 
vessel lumens. 
Defective vessel 
remodelling and Dumont et a1. VEGFR-3 E10.5-EI2 Vasculogenesis organization; irregular (1998) large vessels with 
defective lumens. 
Defective vessels 
remodelling, Davis et a1. 
Angl E10.5 Angiogenesis organization, and (1996); Suri et 
sprouting; heart a1. (1995). 
trabeculation defects. 
Poor vessel integrity, Maisonpierre et Ang2 E12.5-P1 Maturity edema, and 
a1. (1997). haemorrhage. 
Poor vessel integrity, Puri et a1. 
Tiel E13.5-P1 Maturity edema, and (1995); Sa to et 
haemorrhage. a1.(1995). 
Defective vessel 
remodelling, Dumont et a1. 
Tie2 E1O.5 Angiogenesis organization, and (1994); Sato et 
sprouting; heart a1. (1995). 
trabeculation defects. 
Some defective vessel 
primordia; defective Wang et a1. 
Ephrin-B2 ElO.5 (Vasculogenesis) / vessel remodelling, (1998); Adams Angiogenesis organization, and 
et a1. (1999). 
sprouting; heart 
trabeculation defects. 
Some defective vessel 
primordia; defective OrioH et a1. 
EphB2/EphB3 EI0.5 (Vasculogenesis) / vessel remodelling, (1996); Adams (approx.30%) Angiogenesis organization, and 
et a1. (1996). 
sprouting; heart 
trabeculation defects. 
EphB4 EI0.5 ? ? Aguet (in prep.) 
Table I: Knockout animals from the VEGFR/VEGF, Tie2/ Ang, and Eph/ ephrin families 
exhibited a variety of embryonic defects in vascular development 
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1.3 Role of Cell Adhesion Molecules 
During embryonic development endothelial cells differentiate from a 
common precursors called angioblast and acquire organ-specific properties. 
One of the important determinants of endothelial differentiation is the local 
microenvironment, and especially the interaction with surrounding cells. 
This interaction may occur through the release of soluble cytokine, cell-to-
cell adhesion and communication, and the synthesis of matrix protein on 
which the endothelium adheres and grows. To date four families of cell 
adhesion molecules have been described: integrins, immunoglobulin 
superfamily members, cadherins and selectin. Members of each family have 
been detected in angiogenic vessels. 
Some molecules are expressed in very early stage of development, 
other appear only in advanced stages and are related to a mature, functional 
differentiation level of the cells, and other are required during the 
differentiation process in order to drive the correct endothelial maturation. 
• PECAM-l, Vascular endothelial cadherin (VE-cadherin/ cadherin 5), 
and CD34 are cell-cel1 adhesion molecules expressed very early in 
angioblasts. Although PECAM-l and CD34 are also present in different 
haemopoietic cell types, VE-cadherin is most specific for endothelium (15, 
162, 322). The function of the mucin-like CD34 molecule in embryonic 
capillaries is not well understood, while VE-cadherin and PECAM-1 
are probably involved in homotypic endothelial cell adhesion and in the 
25 
formation of inter-endothelial junctions, which are important for lumen 
formation, cell polarity and vascular permeability. 
• During vasculogenesis fibronectin and its receptor aSpl integrin are 
required for vascular development and mouse embryo lacking their 
expression die in utero for early vascular defects (104, 317). In addition, the 
~l integrin is important in vasculogenesis and lumen formation of the dorsal 
aorta(70). More recently the integrin aVp3 was found to be upregulated in 
angiogenic endothelium and seems to playa determinant role in tumour 
angiogenesis (36). 
• Laminin, vitronectin and other extracellular matrix molecules are produced 
by endothelial cells in later vasculogenesis stages, and an intact basal lamina 
is a characteristic feature of a mature blood vessel (245). These molecules 
may not only have important functions in cell adhesion but also in the 
storage, accumulation and activation of proteases and proteases inhibitors 
such as urokinase and plasminogen activator inhibitor-I, and growth factors 
such as VEGF and cytokines (280). 
• Intercellular adhesion molecule-l and -2 (ICAM-l/CDS4 and ICAM-
2/CDI02) are members of the immunoglobulin gene superfamily identified 
as counter receptors of lymphocyte function-associated Ag-l (LFA-l). LFA-l 
is a member of the integrin family that has an alp heterodimer structure 
and it is expressed on almost all types of leukocytes (268, 271) Important 
adhesive interactions during inflammatory and immune responses are 
mediated by LFA-l and its ligands. 
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ICAM-l is a single chain glycoprotein with a polypeptide core of 
55kDa and it is characterized by five extracellular Ig-like domains. ICAM-l 
can be expressed on many haematopoietic and non-haematopoietic lineages 
such as thymic epithelial cells, fibroblast, vascular endothelial cells, lymph 
nodes and Peyer's patches. In endothelial cells the constitutive ICAM-l 
expression is rather low, but can be induced or up regulated by inflammatory 
mediators such as IL-l, tumour necrosis factor (TNF) and interferon-y (IFN-
I) (187, 234). Identification of ICAM-l expression in unstimulated yolk sacs 
and in cystic embryoid bodies (CEBs) and the increasing of the signal after 
exposure to LPS (127), implies an early ontogeny for the endothelial cell 
signal transduction pathway necessary for leukocyte recruitment and 
suggests a developmental role for this adhesion receptor. 
ICAM-2 is a 60kDa surface glycoprotein member of the Ig-
superfamily with two immunoglobulin-like extracellular domains. Also 
ICAM-2 is broadly distributed on haemopoietic lineage, in particular on 
resting lymphocytes and monocytes, but, in comparison with ICAM-l, its 
expression in tissues is highly restricted to vascular endothelium. Basal 
expression of ICAM-2 on endothelium is much stronger than on leukocytes 
and much higher than that of ICAM-l and is not further increased by 
inflammatory mediators (62). The interaction of LFA-l with ICAM-2 seems 
to be a major component of lymphocytes adhesion to unstimulated cultured 
endothelium (77). Because ICAM-2 is expressed on both high endothelial 
venules in lymph nodes and on vascular endothelium in other tissues, it has 
been hypothesized that ICAM-2 may play an important role in lymphocyte 
recirculation (62). At present there are no evidences of ICAM-2 participation 
in vasculogenesis or angiogenesis processes, while some reports indicate a 
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down-regulation of its expression in tumour associated endothelium (112, 
113). 
Thus, ICAM-1 and ICAM-2 are two endothelial markers: while ICAM-
1 is inducible and its expression levels related to a functional state, and 
ICAM-2 shows constitutive expression. 
1.4 Endothelial Cell: 
Hetero&eneity and different Culture Models 
Endothelial cells, forming the lining of venous and lymphatic vessels, 
actively participate in many important functions in order to control 
specifically the functional homeostasis of the different organs. During the 
differentiation process, endothelial cells acquire specialised properties and 
morphological characteristics. How endothelial cells take different pathways 
of differentiation is still unclear, but one of the important determinants in 
this process, as above mentioned, is the local environment and the 
interaction with surrounding cells. 
Thus, a unique characteristic of endothelial cells is that, although they 
present many common functional and morphological features, they also 
display remarkable heterogeneity in different organs (19). Even in the same 
organ, the endothelium of venous and lymphatic, of large and small vessels, 
veins and arteries exhibits significant differences. Moreover, embryonic and 
adult endothelium is not equally susceptible to differentiation factors (12, 
243). The adult endothelium, nevertheless, can reversibly modify its 
functions on activation (Le. after exposure to inflammatory cytokines), and 
consequently display different and reversible phenotypes (184). Finally, 
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morphological features and responses of endothelial cells are modified also 
in senescence, a mechanism that is still poorly understood (102). 
The identification of specific markers expressed by endothelial cells is 
essential for the recognition of these cells and their different phenotypes in 
vivo and in vitro. At present several molecules suitable for this purpose are 
known. 
A number of these molecules, that includes Factor VIII-related antigen, 
Angiotensin converting enzyme, von Willebrand Factor, thrombomodulin, 
some integrins, PECAM-l, VE-cadherin, are well characterized, but in most 
cases, when markers were identified by monoclonal antibodies directed to 
endothelial cells (e.g. MECA-32, EN4, PAL-E), the antigens were not 
molecularly characterized (20,81, 119, 162,291,305,257,258). 
Most of these endothelial markers are constitutive and essentially 
present in all types of endothelium. Other molecules are expressed only after 
activation by inflammatory cytokines, growth factors or related to the 
functional stage during vasculogenesis or angiogenesis (ICAM-l, VCAM-1, 
E- and P-Selectin, Flk-l, FIt-I, Tie-I) (144, 288, 268, 230, 203). Although an 
evident improvement in this field over the recent years, the number of 
markers rather specific for endothelial cells of different origin, is relatively 
scarce. Different markers has been identified for the characterization of 
highly specialized endothelium such as the high endothelium present in the 
postcapillary venules (HEVs) of lymphnodes and Peyer's patches (GlyCAM-
1, Meca-79), the endothelium of the bone marrow (GM-CSF, PDGF, different 
interleukines) or the endothelium of the brain (HT7, Glut-I) (163, 182, 191, 
260). Nevertheless the number of helpful molecules for the characterization 
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of microvascular endothelial cells or lymphatic vessels endothelial cells is 
particularly limited. To date, the only known marker specific for lymphatic 
endothelial cells is the VEGF-C receptor Flt-4 (140). 
The isolation of endothelial cells from the microvasculature of certain 
vascular regions as well as from lymphatic vessel is still experimentally 
difficult and this is probably one of the major reasons for the present 
difficulties in identifying new specific markers. Another limitation to the 
study of endothelial cell is the fact that, once in culture, these cells tend to 
lose their specialized properties. For all these reason, over recent years, 
many efforts have been made to develop new techniques to isolate and 
culture specific endothelial cells in order to create more realistic in vitro 
models. Even though, isolation and culture of endothelial cells from large 
vessels (e.g. human umbilical vein (HUVEC), bovine and porcine aorta (BAE, 
P AE) has become a routine procedure, endothelium cells from other sources 
are at present being investigated, such as human dermal microvascular 
endothelial cells (HDMEC), endothelial cells isolated from murine brain, lung 
or liver, from lymphnodes or Payer's patches are only few examples of the 
many available (19,241). 
Moreover, to avoid the phenotypical modifications that occur in primary 
culture new culture strategies are developed: e.g. use of specific extracellular 
matrix, of selective media or coculture with other cell types in order to 
reproduce in vitro specific microenvironment (66, 76, 117, 129). Several effort 
have been also done for the establishment of cell lines of transformed 
endothelial cells (41, 96, 131). These cell lines represent useful models that 
allow in vitro studies to investigate the biology and the heterogeneity of 
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endothelial cells. To improve the growth characteristic of primary cells in 
culture different constructs containing the simian virus 40 large T oncogene, 
polyoma middle T anti gene or the E6/E7 genes of human papilloma virus 
have been used. 
The integration of this exogenus DNA, beside growth stimulation and 
immortalization, often induces changes in the karyotypes and in the 
phenotypic features of the cells. At present, many recent studying aim at 
obtaining conditions that could eliminate these undesirable effects. 
It is also important to mention briefly the recent progresses in the 
establishment of in vivo model in order to investigate neovascularization and 
angiogenetic processes. 
The quantification of neovascularization m VIVO has been performed 
primarily by means of the following three approaches: 
• microcirculatory preparations in animals, mostly chick embryo and 
rodents; 
• vascularization into biocompatible polymer matrix implants; 
• excision of vascularized animal or human tissues. 
Several advantages and different limits are evident for each of these 
approaches, and the present research is focused on developing angiogenic 
assays highly reproducible and quantitative. This aspect become relevant in 
order to study the angiogenic/ antiangiogenic activity of different growth 
factors or other substances (e.g. chemokines, extracellular matrix, proteases, 
steroids hormones, some lipids) that seem to playa role in the establishment 
of "angiogenic diseases" (polyartritis, psoriasis, diabetic retinopathy, 
endometriosis) or in tumoral angiogenesis (92-94). 
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As a final remark, it IS relevant the development of 
transgenic/knockout mouse models that has provided powerful insights 
into molecular mechanisms of angiogenesis. 
1.5 Angiogenesis and Vascular Disorders 
Angiogenesis, as previously described, is a fundamental process by 
which new blood vessels are formed from the established microcirculation. It 
is essential and particularly active in a large number of normal processes 
during pre- and post-natal life. In the adult organism, in which the turnover 
of endothelial cells is extremely low and the circulatory tree is established, it 
appears only in specific circumstances: reproduction, wound repair, 
inflammation and colIaterization in response to ischaemic stimuli. Under 
these conditions angiogenesis is highly regulated, i.e. turned on for brief 
periods (days) and then completely inhibited. The process of 
neovascularization is extremely complex and implicate the following event: 
Endothelial cells and pericyte activation; 
basal lumina degradation; 
migration and proliferation of endothelial cells and pericytes; 
formation of a new capillary vessel lumen; 
appearance of pericytes around new capillaries; 
development of a new basal lamina; 
capillary loop formation; 
persistence or involution and differentiation of the new vessels; 
capillary network formation; 
organization into larger microvessels. 
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It is evident that a number of different factors participate in the control 
of angiogenesis in vivo and the control derives from the balance between 
stimulatory and inhibitory substances. The angiopoietic activities of FGF, 
VEGF, PDGF, the E series of prostaglandin, angiogenin and monobutyrin as 
well as the nicotinamide and related compounds are extensively described 
(93). In several cases the molecular mechanism is completely understood, in 
others it is still under investigation. Generally, angiogenic factors act on the 
proliferation and/ or the motility of endothelial cells. 
By contrast, it has been demonstrated that angiostatin, endostatin, 
platelet factor 4, interferon-aHa, interferon-inducible protein 10 and some 
steroids (9, 118, 183,212,274) may inhibit the proliferation of endothelial cells 
and consequently are described as antiangiogenetic molecules. The 
identification of these molecules and the recognition of this biological activity 
lead to an increased interest for the investigation in this field in order to 
develop new therapeutic strategies. 
Thus, many diseases are driven by persistence of unregulated angiogenesis, 
probably due to the failure of a such complex balance. 
In arthritis, new capillary blood vessels invade the joint and destroy 
cartilage. In diabetes, new capillaries in the retina invade the vitreous, bleed 
and cause blindness. Other frequent ocular diseases related to angiogenesis 
are retrolental fibroplasia and neovascular glaucoma. The excessive 
proliferation and shedding of epidermis evident in psoriasis, may depend on 
abnormal capillary growth in the dermis, and capillary proliferation within 
arteriosclerotic plaques which may bleed, contribute to sudden occlusion of 
coronary arteries (93). It is at present absolutely evident that tumor growth 
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and metastasis are angiogenesis-dependent (94, 192). A tumour continuously 
stimulates the growth of new capillary blood vessels for the tumor itself to 
grow (143). Furthermore, the new blood vessels embedded in a tumour 
provide a gateway for tumor cells to enter into the circulation and to 
metastatize to distant sites, such as liver, lung or bone. Endothelial cells can 
also originate tumours for itself with a more or less severe clinical outcome. 
Hemangioma, in which abnormal capillary proliferation appears in 
newborn babies and may persist for up to two years, can in some cases 
cause death from haemorrhage or spontaneously regress. Angiofibroma is a 
more severe tumour and appear in the nasopharynx usually in adolescents. 
Kaposi sarcoma (KS) is probably one of the most severe 
angioproliferative disease and recently, for its association to AIDS, also 
relatively frequent. KS lesions display intense endothelial cell proliferation, 
disorganized angiogenesis with migratory spindle cells, interstitial sclerosis, 
often progressing to an angiosarcoma-like stage resembling the Stewart-
Treves syndrome associated with longstanding lymphedema (309). AID5-KS 
patients commonly die with massive pulmonary edema, serus effusions and 
anasarca. 
Human herpesvirus-8 (HHV-8) has been detected in Kaposi's sarcoma 
lesions of all types (AIDS-related, classical and endemic), and consequently 
has been referred to as Kaposi's sarcoma-associated herpesvirus (KSHV) 
(196). 
Cumulative data from epidemiological and serological studies indicate that 
infection by human herpesvirus-8 (HHV -8) precedes development of KS 
(262, 307) and recently was suggested that the expression of KSHV vBcl-2 
may play an anti-apoptotic role in virus infected cells (251, 290) promoting 
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the establishment of the disease. Although these relevant progresses, the cell 
of origin and the nature of KS (multicentric vascular hyperplasia vs. 
neoplasm) remain mired in controversy. The ilKS cell" is considered to arise 
from blood vascular endothelial variants or (most often mentioned) from 
lymphatic (17). 
Whereas the recent explosion of interest in angiogenesis has focused 
almost entirely on the regulation of blood vessel growth and what turns this 
process on and off, it is becoming evident that similar processes and 
probably similar underlying physiochemical signals and mediators must be 
involved also in normal and pathologic lymphangiogenesis (Fig. 4). 
1.6 Lymphangioma 
Disordered lymphangiogenesis range from strangulating cystic 
hygroma, vascular birthmark (Klippel Trenaunay-Weber) syndrome, Kaposi 
sarcoma and Stewart-Treves (lymph)angiosarcoma. Lymphangiomas, like 
their blood vessels counterparts (haemangioma), are common disfiguring 
tumors of childhood and may also arise and enlarge rapidly in adulthood 
(170, 200). Some lymphangioma syndromes follow mendelian inheritance 
(autosomal dominant), whereas others are dysmorphogenic conditions that 
may represent somatic mutations. In vivo behaviour and aggressiveness 
varies between a ductal malformation (e.g. cystic hygroma) and true 
neoplasia ("aggressive" lymphangioma) as these tumors insinuate into 
adjacent tissues and encroach on vital organs. Some lymphangiomas may be 
multifocal or multicenter and occasionally malignant transformation takes 
place (e.g. Maffucci syndrome). Sex hormones, such as exogenous or 
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Figure 4. Lymphangiogenesis disorders. 
Hypothesized links between the pathophysiologic events and sequelae of 
lymph stasis and disturbed lymphangiogenesis, hyperplasia, displasia 
and neoplasia. During a latent period (no overt edema), lymphatic truncal 
dysplasia is accompanied by lymphatic ectasia, muscular dysfunction, 
lymph angiogenesis and intraluminal valve incompetence culminating in 
a persistent protein-rich lymphedema (more than l.Sg/ dl). Superimposed 
opportunistic infection, immunosuppression, and injury with repeated 
lymphangitis promote intractable lymphedema, intense 
(lymph)angiogenesis, lipid deposition and fibrosis, and on rare occasions 
malignant vascular neoplasia. This sequence of events may evolve as a 
local phenomenon as in peripheral lymphedema ("local AIDS") or as a 
multitude of isolated or generalized visceral disorders characterized by 
scar formation and angiohyperplasia and neoplasia including AIDS-related 
syndromes. 
Reproduction from: Witte and Witte. Lymphangiogenesis and lymphologic syndromes. 
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endogenous estrogen (oral contraceptives and puberty hormones) appear to 
stimulate lymphangioma and other angiotumor growth. 
The in vivo behaviour of these tumors, characterized by formation of 
tubes, cystis and other dysplastic structures, can be reproduced in vitro (303, 
304). Whereas normal endothelium from vein, artery, lymphatic and 
microvasculature in vitro exhibits typical contact-inhibited homogeneous 
cobblestone morphology, dysplastic and neoplastic endothelium exhibits a 
more heterogeneous cell population of multiple phenotypes and absence or 
reduced contact-inhibition. This is probably due to the presence of 
transformed phenotype. Lymphangioma derived cells, propagated for long 
periods in culture, exhibit spontaneous lymphangiogenesis in vitro, retaining 
the morphologic characteristic of lymphatic endothelium, albeit with great 
heterogeneity. The percentage of the cell population exhibiting v WF 
positivity is also extremely variable (168). 
These in vitro models are not only useful to study endothelial cell 
structure and function, but also to define the biological behaviour of 
transdifferentiated or transformed lymphatic endothelium. 
At present, this tumor has been described only in humans, while in 
mice only haemangiomas have been reported (124). 
1.7 Freund's Emulsified Mineral Oil Adjuvants 
Historically, the development of Freund's adjuvant emerged from 
studies of tubercolosis in which it appeared that the immunologic responses 
in animals to various antigens were enhanced by introduction into the 
animal living Mycobacterium tubercolosis. Moreover, in the presence of 
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Mycobacterium, the reaction of hypersensitivity obtained was of the delayed 
type, transferable with leukocytes. In studies to measure the effect of 
mineral oil in bringing about delayed-type hypersensitivity to killed 
Mycobacteria, Freund noted that there was a remarkable increase in 
complement-fixing antibodies response, as well as in delayed 
hypersensitivity reaction. These basic principles were applied to improve 
immunologic responses to various added antigens and finally the Freund's 
adjuvant were evolved. Essentially, Freund's adjuvant consist of a water-in-
oil emulsions of acqueous antigen in paraffin (mineral) oil of low specific 
gravity and low viscosity. Drakeol 6VR is a commonly used mineral oil and 
Aracel A (Mannide monooleate) is employed as emulsifer. There are two 
Freund's adjuvants: complete and incomplete, differing for the presence (in 
the complete formulation) of dried, heat-killed Mycobacterium tubercolosis or 
butyricum. 
The discovery of the adjuvant action of Freund's mineral oil emulsions 
fulfilled an important need for increasing antibody response to antigens and, 
at the moment in which it was not yet developed the modem concept of 
safety, found rapid application to experimental vaccines in man (97, 125). 
Only later, in order to assess the safety of Freund's adjuvant, several 
investigation were performed in animals. 
Several publications report various harmful effects following administration 
of Freund's adjuvant or its component (18, 126, 165). Disseminated 
granuloma were recorded to be formed in the lung, liver and kidney of 
rabbit treated once weekly for four weeks by intracutaneous route with 
Aracel A in physiological saline solution and light mineral oil (273). 
Granulomatous proliferative lesions were described in the liver and spleen of 
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mice, in the lungs of guinea pigs and in the lung, brain and liver of hamster 
which received the oil-saline mixture (165). In 1960 and 1961, Potter and 
Robertson and Lieberman et al. (173, 236) respectively have recorded 
appearance of ascites and plasma-cell proliferation in mice of different strains 
following repeated intraperitoneal injection of incomplete Freund's adjuvant 
emulsified with physiological saline solution or with a suspension of 
Staphylococcus aureus. The injection of the adjuvant preparations as well as of 
mineral oil alone was able to induce in mice of BALBI c strain plasma-cell 
neoplasm, with the consequential development of myeloma serum and 
Bence-Jones protein in the urine. 
The tumours in certain mice appeared to evolved from 
lipogranulomatous tissue, appearing in the form of multiple nodules in the 
mesenteries and on the peritoneal surfaces (173). 
Beside these studies model, Freund's adjuvant was used also to assess 
experimental model of diseases with a immunological origin. Administration 
to animals of autologous, isologous, homologous or even related 
heterologous tissue in Freund's adjuvants gives rise to various experimental 
illnesses, termed autoallergic disease, which serve as a model for similar and 
probably related autoimmune disorders in humans (297). The injection of 
Freund's adjuvant into the foodpads of some rat and mouse strains, has 
been recognized as a useful animal model to study arthritis (150, 239). 
Finally, Freund's adjuvant is widely used in different routes and schedules of 
immunization in animals for the production of monoclonal antibodies. 
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The Chemokines 
Endothelial cells line the internal surfaces of blood and lymphatic 
vessels and have long been considered only as a "passive" lining. They were 
attributed negative properties, i.e. to act as a non-thrombogenic substrate 
for blood and were considered to participate in tissue reactions essentially as 
a target for injurious agents. Isolating and culturing endothelial cells from 
various tissues allowed not only in recognition of the wide heterogeneity of 
endothelial cells, but also in studying their complex reactions to a variety of 
activating stimuli. Endothelial cells have now emerged as active participants 
in many physiological and pathological processes. 
Haemostasis, inflammatory reactions, and immunity involve close 
interactions between endothelial and immunocompetent cells . In particular 
ontogeny and leukocyte trafficking require an intimate relationship between 
these two kinds of cells. The bidirectional interactions between leukocytes 
and endothelial cells is mediated by cytokines (184, 186). 
In the large and complex cytokine superfamily an important role is 
carried out by a class of molecules with very distinct effects and 
characterized by common structural feature: the chemokines. 
1.8 General Features of Cbemokines 
Chemokines constitute a superfamily of small, inducible, secreted 
proinflammatory cytokines involved in a variety of immune responses and 
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primarily described as chemoattractans and activators of specific types of 
leukocytes (Fig. 5). Indeed the name chemokine comes from a combination 
of chemotactic and cytokines and chemotaxis or signalling for directed 
migration has been the central concept, besides the structural similarities, 
that distinguishes this class of proteins. At the present time it is conceivable 
that the regulation of white blood cells' motility represents only a fraction of 
the spectrum of their functions. 
Nevertheless, if many cytokines have been discovered by 
observation of their bioactivities, the majority of chemokines have been 
identified by cloning effort. In 1961 was described the first chemokine (PF4, 
platelet factor 4) and only in 1987 the second, IL-8 (67, 321), but as soon as 
few new molecules were identified and the common structural feature 
recognized, the number of chemokines increased rapidly. 
Moreover since 1996, when it has been discovered that some 
chemokine receptors are able to bind HIV viruses, and serve as co-receptor 
for virus entry into the cell, chemokine research received a great and 
decisive impulse (58). Up to now more than 50 distinct chemokines are 
known, and their number is expected to increase significantly in the very 
near future, mainly as a result of the establishment and analysis of expressed 
sequence tag (EST) database. 
Ranging in size from 6-14 kDa (non-glycosylated), chemokines are 
related by primary structure, particularly by the conservation of cysteine 
motifs. The superfamily is divided into four classes by the arrangement of 
these conserved cysteine (C) residues of the mature proteins: 
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• CXC chemokines or a-chemokines, have one amino acid residue 
separating the first two conserved cysteine residues; 
• CC chemokines or ~-chemokines have the first two conserved 
cysteines residues adjacent; 
• C chemokines (y-chemokines) lack two (the first and the third) of 
the four conserved cysteine present in CXC and CC chemokines; 
• CX3C chemokines, have three intervening amino acid residues 
between the first two conserved cysteine residues. 
In the CC and CXC families, two disulfide bonds are present between 
the first and the third, and the second and fourth cysteine residues, 
respectively. 
Within the a-subfamily, the chemokines can be further divided into two 
groups: the first having the characteristic three amino acid sequences ELR 
(glutamic acid-leucine-arginine) motif immediately preceding the first 
conserved cysteine residue near the amino terminus, and the second lacking 
the ELR motif. 
Many of the ELR containing CXC chemokines have been show to be 
chemotactic for neutrophils, while non-ELR CXC chemokines act on 
lymphocytes. 
By contrast, the CC chemokines have been found to be chemotactic 
for monocytes, lymphocytes, dendritic cells, natural killer cells, eosinophils 
and basophils, but not neutrophils. The unique y-chemokine so far reported, 
lymphotactin, shows to be chemotactic for lymphocytes (148), while the 
single CX3C chemokine (fractalkine), has been found to trigger the adhesion 
of T cells and monocytes. Fractalkine is a chemokine recently identified 
through bioinformatics, that unlike other known chemokines, is a type 1 
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membrane protein containing a chemokine domain at the amino terminus 
tethered on a long mucin-like stalk (16, 225). 
Once secreted, most of chemokines are present in solutions in the 
dimeric as well as in the monomeric form. Some u- ( IL-8, GRO-u, PF4) and 
J3-chemokines (MIP-IJ3, RANTES, Mep-l), were analysed by either 
multidimensional NMR or X-ray crystallography (14, 175). As expected from 
the significant degree of sequence identity of these proteins, few are the 
significant differences in the structure at monomer level. When monomers 
form the dimeric protein, these differences play a significative role: the 
quaternary structure of u- and J3-chemokines are entirely distinct and the 
dimer interface is formed by a completely different set of residues. While the 
dimer formed by u-chemokine monomers is globular, the one formed by J3-
chemokine monomers is elongated and cylindrical and these distinct 
quaternary structures are preserved throughout the two subfamilies. For 
some chemokines it was also reported the formation of tetramers 
comprising two dimeric subunits (270). 
Although the biological significance of the dimeric form has yet to be 
established, the difference in the quaternary structures between u- and J3-
chemokines, suggests an explanation for the absence of receptor cross-
binding between the two subfamilies (52). As above reported, CC and CXC 
chemokines act in a preferential way on different target cells and chemokine 
receptor-ligand interactions on inflammatory cells seem to be strictly 
regulated. Chemokines have two main sites of interaction with their 
receptors, one in the N-terminal region and the other within an exposed 
loop of the backbone that extends between the second and the third 
cysteine. Probably the receptor recognizes the loop region first, and this 
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Chemokines superfamily is composed by homologous 8-to-lOkDa proteins that are 
subdivided into families on the basis of the relative position of the cysteine residues in the 
mature protein. In the a-chemokines, the first two cysteine residues are separated by a 
single aminoacid (CXC), whereas in the b-chemokines, the first two cysteine residues are 
adjacent to each other (CC), The C chemokine lymphotactin has only two cysteines in the 
mature protein, and the CXXXC chemokine fractaline has three amino acids separating the 
first two cysteines. Chemokine receptors are G-coupled proteins that are expressed on 
subgroups of leukocytes. At present four human CXC chemokine receptors (CXCXRl 
trough CXCR4), eight human CC chemokine receptor (CCRl trough CCR8) and one CXXXC 
chemokine receptor (CX3CRl) have been identified. In the figure are indicated the target 
cells on which chemokines display chemoattractant activity. Reproduction from: Luster A. 
D. Chemokines-Chemotactic Cytokines that mediate Inflammation. The New England Journal of 
Medicine. 388, 436-444. 
interaction is necessary for the correct presentation of the triggering domain 
that correspond to the N-terminal binding site (264). 
1.9 Chemokine Receptors 
The recent findings of a large number of new chemokines and the 
efforts in understanding all their complex functions, leaded to an increased 
research interest for chemokine receptors. 
Various approaches were used for the investigations of chemokine 
receptors: 
• direct binding and displacement studies with radiolabelled ligands 
and unlabelled competitors; 
• signal transduction studies attempting to predict the number of 
distinct receptors based upon Ca++ signal desensitization profiles in 
response to various chemokines; 
• molecular cloning; 
• structure function studies employing mutagenesis techniques. 
At the present time, five receptors for CXC chemokines (CXCR) and 
eight receptors for CC chemokines (CCR) have been characterized (201, 237, 
254). 
All chemokine receptors are integral membrane glycoproteins (via N-
linked glycosylation), with a heptahelical structure snaking through the 
membrane (7 Trans Membrane structure), the N-terminus on the 
extracellular face and the C-terminus on the cytoplasmic side of the 
membrane. Chemokine receptors, mainly expressed in immune cells and 
associated tissues, with a general average at 350 amino acids and a molecular 
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weight of approximately 40 kD, are smaller members of the rhodopsin-like, 
100 G-protein coupled receptors family (4) (Fig. 6). 
It is known that different G protein complexes exist which can bind to 
a given 7fM receptor. The 7fM receptor could be considered to be an 
adapter molecule which must discriminate between external ligands (the 
chemokines) and internal ligands (the G protein complexes) in order to 
transmit the appropriate signal to the cell (33,63,201). 
When the signal is coupled to a Gai2 G-protein type, sensitive to 
Bordetella pertussis toxin, leads the signalling cascade to activation of 
phosphatidylinositol-specific phospholipase C, protein kinase C, small 
GTPases, Src-related tyrosine kinases, phosphatidylinositol-3-0H kinases and 
protein kinase B. Phospholipase C activates two second messengers: inositol-
1,4,5-triphosphate, which releases Ca++ with a transient rise of the cytosolic 
Ca++ concentration, and diacylglicerol, which activates protein kinase C. 
Ca++ mobilization is determinant for superoxide production and cellular 
degranulation. Phosphatidylinositol-3-OH kinases can be activated also by 
the ~y subunits of the G proteins, small GTPases or Src-related tyrosine 
kinases. The chemokine signalling circuit include also the activation of small 
GTP-binding proteins of the Ras, Rac and Rho families. Rac and Rho are 
involved into cytoskeletal rearrangements through regulation of actin-
dependent processes and the consequential membrane ruffling and 
pseudopods formation that is required for cellular migration. In leukocytes, 
Rho family members relay signals from chemokine receptors also to cell-
surface integrins, which trigger rapid adhesion before direct migration. 
Besides, the involvement of chemokine in cellular differentiation and 
proliferation, is due to the ability of G protein-coupled receptors to activate, 
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Chemokines mediate their activities by binding to target cell 
surface chemokine receptors that belong to the large family 
of G protein-coupled, seven transmembrane (7 TM) domain 
receptors. Based on the receptor nomenclature established at 
the 1996 Gordon Research Conference on chemotactic 
cytokines, the chemokine receptors that bind C-X-C 
chemokines are designated CXCRs and the receptors that 
bind C-C chemokines are designated CCRs. In addition, the 
Duffy blood group antigen (DARC) has been shown to be an 
erythrocyte chemokine receptor that can bind selected C-X-
C, as well as C-C chemokines. Leukocytes have generally 
been found to express more than one receptor type. The 
various CXCRs and CCRs are known to exhibit overlapping 
ligand specificities. 
via an unidentified tyrosine kinase connection, mitogenic stimuli through the 
Ras/Raf/Map kinase pathway (29, 157, 164,204,279,312). 
From the evidences derived from different studies, it emerges that 
most receptors recognize more than one chemokine, and several 
chemokines bind to more than one receptor, indicating once more that 
complexity and versatility are characteristic of the chemokine system (237, 
254). It is relevant to note that CXC- and CC-chemokine receptor only 
recognize chemokines of the corresponding subfamily. 
It is possible to categorize the known chemokine receptors into four 
separate classes in relation to the chemokine binding relationship . 
• The class of specific receptors, which bind only one known ligand of 
the chemokine family. This group contains only two examples: the 
CXCRl(IL-8 receptor A), and the CXCR4 (LESTR/fusin). 
• The class of shared receptors, which are able to bind more than one 
chemokine within either the CXC or the CC subfamily. To this group belong 
the largest number of known receptors to date. The CXC2 receptor (IL-8 
receptor B) binds to all E-L-R CXC chemokines described, while CXCR3 
binds to CXC chemokines in which the E-L-R domain is not present. All the 
CC receptors (CCRI-CCR8) known belong to this group. 
• The Duffy blood group antigen (DARC), originally described as an 
erythrocyte chemokine receptor, is the only promiscuous receptor 
characterized by binding properties to chemokine ligands either CXC or C C 
branches (209). 
• Virally encoded chemokine receptors represent shared receptors 
that have been transduced into the viral genomes during evolutionary 
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history. At present time two receptors are described: a CC receptor encoded 
by a cytomegalovirus open reading frame CMV US28 , and a CXC receptor 
encoded by Herpes Saimiri virus open reading frame (4, 233). 
There are some receptors homologous to chemokine receptors for 
which no ligands have yet been identified (orphan receptors). Similarly there 
are new chemokines, such as ClO, of which their receptors are also 
unknown. 
The presences of receptor mRNA and immunodetectable receptor 
protein in the membrane fraction are considered to be acceptable evidence 
for a cell type to be a specific target for a given chemokine. 
eXCR1 and CXCR2 are expressed by neutrophils but not by B and T 
lymphocytes, while CXCR3 is highly expressed by IL-2-activated T 
lymphocytes (132, 176, 202). CXCR4 (LESTR/fusin), was originally 
discovered as an orphan receptor with structural similarity to chemokine 
receptors; subsequently it was identified as a necessary cofactor for entry of 
T cell-tropic HIV virus into CD4+ cells, and the chemokine PBSF/SDF-1 was 
described as its ligand(27, 85, 213). 
The CeRl (MIP-la/RANTES receptor) is expressed on monocytes, 
neutrophils or eosinophils, while eCR2A and CCR2B are expressed only on 
monocytes (47, 211, 314). eCR3 is the receptor for eotaxin, a chemokine 
molecule that act specifically on eosinophils (235). CCR4, CCR6 and CCR7 
can be expressed by T lymphocytes, depending on the state of cell activation, 
and by B lymphocytes. The ligands of these molecules, respectively T ARC, 
LARC and ELC, are chemokines expressed constitutively in lymphoid tissues 
(lymphnodes, thymus, Peyer's patches, T cell areas of the spleen) and their 
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apparent selectively for receptors expressed by lymphocytes suggest that 
are involved in the regulation of physiological lymphocyte traffic (320). 
CCR5 mediates the activity of MIP-1a., MIP-l~ and RANTES in 
primary adherent monocytes, while is not expressed in neutrophils and 
eosinophils. Recently it has also been shown that CCR5, as well as CXCR4, 
plays a critical role in HIV virus entry into the target CD4 + cells. CXCR4, as 
reported above is expressed in CD4+ T cells, while CCR5 is described to be 
the co-receptor for macrophage-tropic HIV -1 virus. This finding is consistent 
with the report identifying the CCR5ligands (MIP-la., MIP-l~ and RANTES), 
as the major suppressive factors produced by CD8+ T cells for macrophage-
tropic, but not T cell tropic, HIV isolates (28, 53). Studies on individuals 
repeatedly exposed to HIV but remaining uninfected, revealed a 
homozygous defect in their CCR5 gene, leading to the expression of a 
truncated CCR5 molecule, undetectable on cell surfaces. In these individuals 
the LESTR/fusin receptor have been shown to be unaltered and the CD4+ T 
cells to be easily infected by T cell-tropic viruses (65). All these data suggest 
that macrophage-tropic isolates are likely to be the viruses responsible for 
the transmission of HIV-1 viruses and that CCR5 is a determinant factor in 
the transmission and progression of AIDS (Fig. 7). 
1.10 Gene location 
Genes for many CXC and CC chemokines have been found to be 
clustered. Most of the CXC chemokines genes have been mapped to human 
chromosome 4q, and those for many CC chemokines on human 
chromosome 17q (mouse chromosome 11). Exceptions to these cluster 
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Figure 7. Chemokine Receptors as Obligate Coreceptors for HIV Entry 
into Cells and Chemokine Inhibition of HIV Entry. 
HIV glycoprotein 120 (gp 120) binds to CD4, resulting in a conformational change 
that expose the V3 loop in gp120 and permits subsequent interaction with a 
chemokine receptor. To gain entry into cells, macrophage tropic (M-tropic) HIV-l 
uses CCR5 predominantly, and the T-cell-tropic (T-tropic) HIV-l uses CXCR4 
predominantly. Macrophage inflammatory proteins (MIP) -In and -1~ and the 
RANTES (regulated upon activation normal T-cell expressed and secreted) 
chemokine, ligands for CCR5, block M-tropic HIV-l from entering cells. Stromal-
cell-derived factor 1 (SDF-1), a ligand for CXCR4, blocks T-tropic HIV-l from 
entering cells. 
Reproduction from: Luster A. D. Chemokines-Chemotactic Cytokines that mediate Inflammation. 
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includes some CXC and CC molecules, nevertheless the clusters of 
chemokine genes suggest that many chemokine family members arose 
through gene duplication and subsequent divergence. The gene for 
lymphotactin has been localized on chromosome 1 both in human and 
mouse, while that for fractalkine on human chromosome 16q and mouse 
chromosome 8 (288). 
1.11 General function of Chemokines 
A large number of information about chemokines and their functions 
arose from the recent progress in this field and demonstrates the complexity 
of this cytokine subfamily. Chemokines are produced by a variety of cell 
types and have overlapping activity. In certain cases peculiar functions, as 
the inhibition and stimulation of blood vessel formation (angiogenesis) (153) 
or leukocyte maturation in the bone marrow (myelopoiesis) (37,293), were 
attributed to chemokines, but most chemokine actions that have been 
reported are related to leukocyte migration and recruitment. (255, 269) (Fig. 
8). 
The circulatory and migratory properties of leukocytes have evolved 
to allow efficient surveillance of tissues for infectious pathogens and rapid 
accumulation at sites of injury and infection. Lymphocytes, in particular, 
continuously patrol the body for foreign antigens recirculating from blood, 
through tissue, into lymphatic vessels, and back to blood (42). 
The in vivo requirements for cell trafficking are complicated and need 
a coordinate sequence of events: 
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Figure 8. Chemokine Regulation of Leukocyte Trafficking. 
Chemokines are secreted at sites of inflammation and infection by resident tissue 
cells, resident and recruited leukocytes, and cytokine-activated endothelial cells. 
Chemokines are locally retained on matrix and cell-surface heparan sulphate 
proteoglycans, establishing a chemokine concentration gradient surrounding the 
inflammmatory stimulus, as well as on the surface of the overlying endothelium. 
Leukocytes rolling on the endothelium in a selectin-mediated process are brought 
into contact with chemokines retained on cell-surface heparan sulphate proteoglycans. 
Chemokines signalling activates leukocytes integrins, leading to firm adherence 
and extravasion. The recruited leukocytes are activated by local proinfiammatory 
cytokines and may become desensitized to further chemokine signaling because 
of high local concentrations of chemokines. The Duffy antigen receptor for chemokines 
(DARC), a non signaling erythrocyte chemokine receptor, functions as a sink, 
removing chemokines from the circulation and thus helping to maintain a tissue-
bloodstream chemokine gradient. 
Reproduction from: Luster A. D. Chemokines-Chemotactic Cytokines that mediate Inflammation. 
The New England Journal of Medicine. 388, 436-444. 
a) circulation 
b) adhesion 
c) diapedesis 
d) migration. 
In each of this steps the chemokine presence has a relevant role. 
a) Leukocytes must overcome hemodynamic forces in order to 
adhere to the endothelial cell surfaces lining the vessel wall. At this step 
molecules of the selectin family (L-selectin, P-selectin, E-selectin), mediate the 
attachment or tethering of flowing leukocytes to the vessel wall, through 
labile adhesion that lead leukocytes to roll in the direction of flow (269). 
Chemokines, released by the activated endothelial cell in response to the 
inflammatory stimuli, are sequestered in a solid phase by its binding to cell 
surface proteoglycans or by association with heparin (280) and form 
chemical gradients. Such immobilization allows them to be presented to the 
marginating leukocytes and to convert the initial rolling interaction of 
leukocytes in a stable binding to surface integrin adhesion molecules of the 
endothelial cell. 
b) Specific chemokine receptors present on the target leukocyte 
interact with chemokines inducing a rapid accumulations of intracellular free 
calcium (267). Calcium mobilization is a critical intracellular event that not 
only stimulate degranulation, shape change, actin polymerization and 
respiratory burst (289), but also regulate the expression of adhesion 
molecules on leukocyte surfaces. Chemokines upregulate adhesiveness 
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through integrins by inducing fusion of secretory granules with the plasma 
membrane of activated cells. The expression of molecules such as MAC-1 
(CDllb/CD18), LFA-l, p150,95 on the surface of leukocytes, enable these 
cells to adhere to the endothelium integrin ligands (ICAM-l, ICAM-2, 
ICAM3), before migrating into the tissues (269). 
c) Changes in cell shape following chemokine stimulation is due to a 
dynamic remodelling of the cytoskeleton with the formation of cytoplasmic 
projections termed "uropods" or "lamellipodia". This morphological 
modification allows adherent leukocytes to cross the endothelial lining 
(extravasion or diapedesis), and pass into the tissue space. 
d) Once leukocytes have crossed the vascular endothelium into the tissue 
their migration to the focus of stimuli is directed by the gradient of 
chemokines molecules present within the extracellular matrix. 
Over the past years the role of chemokines, in addition to the one described 
in infection and in inflammation, it has been also recognized their 
participation in the regulation of lymphocyte traffic. T and B lymphocytes, 
during their development and differentiation move through non-lymphoid 
and lymphoid tissues (Fig. 9). Several novel lymphocyte-selective 
chemokines, that are expressed constitutively at high levels in the thymus, 
lymphnodes and other lymphoid tissues have been identified (123, 136, 248, 
318). Most of these chemokines (TARC, ELC, 6Ckine, and LARC) belong to 
the CC subfamily and it is conceivable that may be involved in driving the 
trafficking of T lymphocytes. 
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Figure 9. Lymphocytes Homing and Trafficking. 
Naive lymphocytes home to specific microenvironments within secondary 
lymphoid tissues and recirculate through these sites until they either die or 
encounter their specific antigen. Unlike naive cells, memory and effector T 
(and probably B) cells can efficiently extravasate in tertiary (extralymphoid) 
inflammatory sites, with subset displaying targeted trafficking through, for 
example, inflamed skin, intestinal mucosa, pulmonary tissues and joints. 
Antigen activated B cells may home to specialized environments in the outer 
T zone during primary responses, or may colonize germinal center sites of 
hypermutation, affinity maturation, and cell memory differentiation. Less 
abundant, specialized lymphocytes subset include yo T cells in the mouse, 
and subset of gut intraepithelialleukocytes. That may be target directly from 
their origin in the thymus or bone marrow to reproductive, cutaneous, 
intestinal or other tertiary tissues (not illustrated). The extralymphoid effector 
sites of selective homing include (at least) skin, lung, intestinal lamina propria, 
and synovium. PALS, Periarticolar lymphoid sheath. Ag, antigen. 
Reproduced from: Lymphocytes Homing and Homeostasis. Butcher E.C. and Picker, L.J. 
Science.272,60~ 
The specific expression of DC-DK1 by dendritic cells at the site of 
initiation of an immune response, combined with its chemotactic activity for 
naive T cells (3), suggests that chemokines like DC-DK1, play an important 
role in the induction of immune responses. 
BCL a new CXC chemokine that is secreted by lymphoid tissue cells 
and selectively bind to the CXCRS receptor (BLR1) expressed in B 
lymphocytes, is another reported example of a tissue specific function of the 
chemokines (llS). Finally, an abnormally low number of B-Iymphocytes and 
a severely defective lymphopoiesis, was reported in mice lacking the SDF-1 
gene, suggesting that this chemokine, previously described as growth 
factors for B-Iymphocytes progenitors, may be involved in directing 
progenitor cells into the appropriate maturation sites in the bone marrow 
(20S). 
1.12 Other chemokines activities 
Not all of the known properties of the chemokines involve leukocytes 
migration; here it will be briefly reported other non-chemotactic properties 
of chemokines. 
• Haemopoiesis 
SDF-1 (for Stromal Derived Factor I), in the two forms (ex and ~) 
generated by alternative splicing, is a CXC chemokine constitutively 
expressed in a broad range of tissues. As above mentioned SDF-1 is involved 
in B-Iymphocytes maturation, but more generally this chemokine was 
described to support the colonization of the bone marrow by haemopoietic 
precursors during embryogenesis (S). 
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Another CXC chemokine, platelet factor 4 (PF4), has been reported to 
have a large spectrum of activities, induding, differently from SDF-l, an 
inhibitory effect on haemopoietic processes (106). Inhibition of 
megakaryopoiesis, as well as suppression of colony formation by immature 
myeloid progenitors after GM-CSF stimulation, has been documented. 
The MIP proteins (CC chemokine subfamily), have been reported to 
have some interesting effects on haemopoietic precursor cells. MIP-l and 
murine MIP-2, synergistically with GM- and M-CSF, are able to enhance 
CFU-GM. MIP-1a. in the monomeric form reversibly inhibits the 
proliferation of stem cells, but this suppressive effect does not take place 
when the chemokine is in the dimeric form (38, 110). 
• Pyrogenic effects 
To the MIP-1 proteins have been ascribed also pyrogenic activities. 
The pharmacological aspects of this activity have been investigated and the 
evidence from these studies suggest that MIP-1 exerts its febrile effects by 
some direct interaction with the hypothalamus (194). 
• Chemokines in Tumour Biology 
In recent years some experiments have been performed in order to 
establish if chemokines secretion can be involved in inhibition of tumour 
growth in vivo. Tumour derived cells, which are normally tumorigenic in 
nude mice, were engineered to produce different CC chemokines such as 
MCP-1 and RANTES and were inoculated into the animal model. In all cases 
the chemokine-bearing tumour cells failed to grow, while the unmodified 
cells formed large tumours (247). The observations that a number of 
monocytes and macrophages were associated with the injection site and that 
the co-administration of antibodies, which inhibited T-cell function or 
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macrophage migration, rescued the tumour growth, confirmed that the 
inhibition of tumour growth was an immune-mediated phenomenon 
induced by the chemokines (199). These data suggested a possible use of 
chemokines in anti-tumour strategies. However these results were not in 
agreement with different finding that many tumour cell as well as primary 
tumours are producers of chemokines 
Whether tumour cells may derive any advantage from chemokines 
production, is not yet clearly determined yet, but an involvement of 
chemokines in beginning the metastatic process by drawing the migration of 
tumoral cells into vessels, and the angiogenetic properties of some of these, 
has been suggested by several authors to play an important role (111). 
Finally, a CXC chemokine referred as MGSA (Melanocyte growth 
stimulatory activity), or GRO-a was described as an autocrine growth factor 
for a human melanoma cell line (242). 
From these findings it is evident that chemokines' role in tumour 
biology is still not well understood, but the increasing interest in their 
therapeutic potentials will certainly lead to a better defined overall picture. 
• Angiogenesis 
Endothelial cells produces various chemokines in response to signals 
representative of inflammatory reactions, immunity and thrombosis (184). 
Furthermore recent evidences suggest that some chemokines may affect 
endothelial cells functions. IL-8, GRO-a, and other CXC chemokines were 
reported to induce endothelial cells migration and proliferation in vitro and 
to be angiogenic in vivo (153). PF4 and IP-10 (Interferon y-inducible protein 
10), were shown to have angiostatic properties in vivo (295). As described 
above, within the CXC subfamily, it is possible to identify a group of 
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molecules in which the ELR (glutammic acid-leucine-arginine) motif is highly 
conserved, and a second lacking such an ELR motif. Recent result suggest 
that the presence or absence of an ELR motif dictate whether CXC 
chemokines induce or inhibit angiogenesis. 
There are no findings that CC chemokines affect endothelial cells 
migration and proliferation. 
• Chemokines in Disease 
While inflammation and leukocyte accumulation is essential to innate host 
defence against microbes, the presence of infiltrating leukocytes in non-
infectious disorders may be deleterious to the host, leading to impaired 
organ function and potential mortality. 
It is at present established that certain CC chemokines (RANTE5, 
MCP-l, MCP-3, eotaxin), exhibit potent promigratory and activating 
potentials for basophils, eosinophils and T cells, the cells most often 
associated with respiratory pathologies and allergic disorders (14, 178, 180, 
235) (Fig. 10). 
Rheumatoid arthritis (RA) is an autoimmune disease characterized by 
joint inflammation and destruction that is related to the sequestration of 
leukocytes within the developing pannus and synovial space. A number of 
studies have determined that both CXC and CC chemokines are significantly 
present in RA, even if their involvement in the pathogenesis of this disorders 
is still unclear (152). Recent data demonstrate that MIP-1n and MIP-2 
contribute to the development of experimental arthritis in mice (146), and 
this finding suggest that these chemokines may play a similar role in the 
pathogenesis of human RA' 
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Figure 10. Role of Chemokines in Various Inflammatory Disease. 
Inflammatory disease are characterized by selective accumulation of 
leukocytes subgroups, a process controlled by the expression of certain 
chemokines. Each disease has a characteristic inflammatory infiltrate in 
which chemokine messenger RNA or protein concentrations have been 
shown to be up-regulated. 
Reproduction from: Luster A. D. Chemokines-Chemotactic Cytokines that mediate 
Inflammation. The New England Journal of Medicine. 388,436-444. 
Finally, ischemia/reperfusion injury contributes to the 
pathophysiology of many clinical disorders, including myocardial infarction, 
stoke, mesenteric ischemia, peripheral vascular disease, organ 
transplantation and circulatory shock. 
Investigations have shown that anoxia/hyperoxia (simulating 
ischemia/reperfusion) can lead to a significant production of IL-8 by 
mononuclear and vascular pulmonary endothelial cells (145, 190). The high 
level of IL-8 expression correlates with a relevant neutrophils extra vas ion 
and tissue injury, that are prevented by immunization of the animal models 
with neutralizing Abs to IL-8 (259). 
1.13 q-Chemokines 
• KC: This protein is the ELR-CXC murine chemokine homologous of 
the human MGSA (Melanoma Growth Stimulatory Activity)/ GRO-
a. chemokine. 
The KC gene is localized on chromosome 5 and its mRNA is 892 bases long 
with a cds that encodes a precursor protein of 96 amino acids (10.236 daltons) 
(218,288). 
The 72 amino acids mature KC protein is secreted by different cell types 
(fibroblast, macrophages, endothelial cells), after induction of agents 
associated with wound healing and inflammatory response such as serum, 
PDGF, y-interferon and bacterial enterotoxins. KC, binding to the IL-8R type 
B homolog specific receptor, induces chemotaxis, respiratory burst and 
overexpression of CDllb/ CD18 in neutrophil (107, 198). 
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Although the high sequence similarity between the human MGSAI gro 
a gene and the mouse KC gene (65%), the transcriptional control of the gene 
is different (214) and the mitogenic activity on melanocytes reported for 
MGSA, was not described for the mouse chemokine. 
- MIP-2: Macrophage Inflammatory protein-2 a and ~ are the 
products of the GRO-~ and GRO-y genes described in humans, in mouse a 
single MIP-2 chemokine was reported. The murine MIP-2 genomic clone 
displays the canonical four exonl three introns structure typical of other 
genes in the chemokine (l subfamily. The promoter region contains an LPS-
responsive element in the region that contains a conserved NF-kB consensus 
motif highly conserved in all three human GRO genes and described also in 
the mouse KC gene. MIP-2 RNA has 1008 bp with an open reading frame of 
300 bp, which encodes for a 100 amino acids precursor protein. The mature 
MIP-2 has 73 amino acids. 
Several inflammatory stimuli induce the rapid and marked increase in MIP-2 
secretion by mast and mesangial cells, alveolar macrophages and epidermal 
cells (313) with a rapid and evident effect on neutrophils and basophils. 
Probably MIP-2 and KC chemokines provide in mouse the same functions of 
IL-8, the major neutrophil chemoattractant in humans, that in mouse has not 
been identified. In order to establish MIP-2 contribution in different 
disorders, many studies were performed on animals (84, 302). MIP-2 binds 
with high affinity to murine IL-8 RB homologue (278). 
-CRG-2/C7: The product of this gene is the murine homologue of the 
human gamma interferon inducible protein-l0 (IP-I0). The gene has the 
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above described classical organization. The mature protein, which lack the 
ELR domain, is formed by 77 amino acids and binds to epithelial, endothelial 
and haematopoietic cells via a specific IP-lO/Mig receptor (CXCR3) (83). The 
CXCR3 is highly expressed in IL-2 activated T lymphocytes and this finding 
suggest that IP-10 (CRG-2) is involved in the selective recruitment of effector 
T cells (177). IP-10 act also on monocytes and NK cells, but not neutrophils. 
Cytokines, growth factors, bacteria products, viruses and other stimuli 
induce IP-10 chemokine secretion by endothelial cells, fibroblasts and 
monocytes, but relevant is the presence of spontaneous high levels of IP-10 
transcripts found in lymphoid organs (spleen, thymus, lymph nodes) (103, 
281). 
Several investigations were performed to evaluate the IP-10 role in animal 
model of inflammatory related disease (288). 
• Mig-I: Interferon-gamma induces in monocytes and macrophages 
the expression of Mig-1 (mono kine induced by interferon-gamma), a CXC 
chemokine active as chemoattractant for activated T cells. This molecule is 
functionally related to IP-10, with which is shares a receptor, CXCR3. The 
RNA open reading frame encodes for a 126 amino acids precursor protein, 
while the mature form has 105 amino acids (82, 83). 
• .BeL; B-Iymphocytes chemoattractant is a novel chemokine, that is 
highly expressed in the follicles of Peyer's patches, spleen and lymph nodes. 
BCL strongly attracts B lymphocytes while promoting migration of only a 
small numbers of T cells and macrophages. It is the first chemokine to be 
identified that is selective towards B cells. BCL binds to the orphan 
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chemokine receptor BLR-1 (Burkitt's lymphoma receptor 1), acting to direct 
the migration of B lymphocytes to follicles in secondary lymphoid organs. 
The 1.16 kb RNA encodes for a 109 amino acids proteins (116). 
1.14 ~-Chemokines 
• m is the murine homologue to human MCP-1 (Monocyte 
chemoattractant protein-I), a CC chemokine that plays an important role in 
chronic inflammatory disease controlled by mononuclear leukocytes. After 
stimulation with different cytokine or cytokine inducers (bacterial 
enterotoxins, growth factors, viruses, LPS), MCP-1 OE), is secreted by 
various cells types, including fibroblasts, epithelial cells, leukocytes, 
keratinocytes, endothelial cells, smooth muscle cells, as well as tumour cells 
(254). MCP-1 is major chemoattractant for monocytes, T lymphocytes, 
dendritic cells and basophils, in which induces also a histamine release (14, 24, 
45). The murine IE gene is located on the distal portion of chromosome 11 
and it contains three exons; the RNA when spliced is either 594 or 797 bases 
and encodes for a 148 amino acids precursor protein that matures in the 125 
amino acids form. Like others CC chemokines, MCP-1 binds to the shared 
receptors CCR1, CCR2, DARC and to the virally encoded US28 (159). 
MCP-1 (JE) is a prototypic ~-subfami1y chemokine and over the past 
years was extensively studied for its expression and contribution in humans 
and animals disease (288) . 
• RANTES: (Regulated on Activation, Normal T-cell Expressed and 
Secreted), is a chemokine originally identified by molecular cloning as a 
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transcript expressed in T, but not in B lymphocytes. A different name, TY5, is 
also used to define the murine homologue. It is the only p-chemokine 
present in platelets, and shows a potent chemotactic and activating 
properties for basophils, eosinophils, NK and dendritic cells. The murine 
RANTES is the product of the Scya5 gene that is located on chromosome II, 
and is organized into three exons and two introns; the mRNA encodes for a 
protein that in the mature form display 68 amino acids. The expression of 
RANTES is induced by cytokines (JL-l, TNF-a, IFN-y), thrombin, PMA or 
PHA into several cell types like T lymphocytes, epithelial cells, fibroblasts, 
mesangial cells and some tumour cells. RANTES binds to the CCRl, CCR3, 
CCR5, DARC and US28 receptors inducing chemotaxis, but also expression 
of adhesion molecules, enzymes release or degranulation into target cells 
(142,237,249). RANTES expression was described in several human diseases 
as rheumatoid arthritis, in acute renal allograft rejection and in asthmatics 
and allergic subjects (14, 275). 
Finally, it was observed a HIV -suppressive effect of RANTES that synergize 
with MIP-la and MIP-1P in competition with macrophage-tropic HIV 
isolates for CCR5 binding (53) . 
• MIP-a and MIP-6: Macrophage inflammatory protein alpha and beta 
are members of the CC chemokines subfamily that share 70% homology; 
the murine counterparts are respectively the SISa and the H-400 molecules. 
Despite the structural similarity, MIP-la and MIP-lP show significant 
differences in their functions. MIP-lP is inactive, unlike MIP-la, in the 
activation of neutrophils. MIP-la inhibits early haemapoietic progenitor 
growth, whereas MIP-lP potentiates it. In terms of HN-suppressive effects, 
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both molecules seem to have a synergistic effect (53). Secretion of both 
molecules is induced by several inflammatory stimula (cytokines, bacterial 
products and others), in a wide range of cell types like fibroblasts, 
lymphocytes, monocytes, smooth muscle cells. 
Both murine MIP-la and MIP-l~ genes are located on the distal portion of 
the chromosome 11 near the Hox-2 gene complex, and display the same 
structure with three exons and two introns. The mature secreted forms have 
68 and 69 amino acids. MIP-1a and MIP-l~ bind to the same receptors 
(CCRl, CCR5, U528), with the exception of CCR4 to which bind only MIP-la 
(208,300). 
Both molecules are extensively studied, and a number of data are available 
about their regulation of expression, the expression in several disease (in 
humans and in animal models), and biological effects in vivo and in vitro 
(254,288) 
e6Ckine/Exodus-2/SLC: 6Ckine, also named SLC (Secondary 
lymphoid-tissue chemokine) and Exodus-2, is a CC chemokine recently 
discovered independently from the EST database by three groups. 6Ckine 
contain the four conserved cystein characteristic of ~-chemokines plus two 
additional cystein in its long carboxyl-terminal domain. Mouse cDNA 
encodes a 133 amino acids protein with a 23 residue signal peptide that is 
cleaved to generate the 110 amino acids mature protein. This chemokine is 
highly expressed in lymphoid tissues such as lymph nodes, spleen, appendix 
and (only in mouse) lung. Unlike most CC chemokines, 6Ckine is not 
chemotactic for monocytes, macrophages and B cells, but acts on thymocytes 
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and in vitro activates T cells. Recently was reported that 6Ckine/SLC is an 
agonist for the MIP-3~ receptor CCR7 (43, 123). 
-C10: this murine chemokine belongs to the Macrophage 
Inflammatory Protein (MIP)-related protein-2 (MRP-2) subfamily, and only 
recently has been isolated a novel human C-C chemokine (MIP-1 delta), that 
probably corresponds to the human homologue (301). C10 transcripts were 
identified in bone marrow cells, myeloid cell lines, T lymphocytes and 
macrophages. Although CIO is a CC chemokine, the regulation of its 
expression differs from the one reported for other molecules of the same 
subfamily. MIP-1u, RANTES, JE are all induced by LPS treatment of bone 
marrow-derived macrophages (BMM) and/or resident peritoneal 
macrophages (RPM), LPS stimulation of CIO was never observed. 
Conversely IL-3 and GM-CSF strongly induce C10 in both macrophage 
populations, whereas MIP-1a, RANTES and JE show only a weak induction 
restricted to BMM. Finally was reported that macrophage stimulation by IL-4 
induce a selective enhancement of CIO secretion, but fail to stimulate any of 
the other CC chemokines (221, 222). These data suggest that C10 may have 
distinct functions in host defence, but at present its biological significance is 
not know. 
Linkage studies showed that the CIO genes (Scya6) is closely linked to the 
Scya2 locus on mouse chromosome 11, as other members of the beta-
chemokine family, but in contrast with the common three-ex on genomic 
structure, CIO contains a novel second exon that was not previously 
described (23). The precursor protein shows 116 amino acid residues, of 
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which 21 belong to the signal peptide. To date the C10 binding receptor is 
still unknown. 
1.15 'Y-Chemokine 
• Lymphotactin: is the only example of the 'Y-chemokine subfamily, it 
shows similarity to some members of the ~-chemokine, but it lacks the first 
and third cysteine residues characteristic of the others chemokines. The 
murine Un gene maps in the distal region of chromosome one; the mRNA, 
of approximately O.9kb, is exclusively expressed in activated thymic CD8+ 
CD3+ cells and CD8+ CD3+ T cells derived from the spleen. Functional 
analysis demonstrate that lymphotactin is chemotactic for lymphocytes but 
not for monocytes, a characteristic that makes it unique among chemokines. 
The structural features predict the cleavage and secretion of a mature Ltn 
protein of approximately 10 kD. Lymphotactin bind to XCRI a recently 
described receptor (148, 149, 319). 
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Chapter 2 
Materials and Methods 
2.1 Animals and Tumour Induction 
Animals of Balb / c, CBA, Swiss and ASN strains were obtained from 
JacKson Laboratories, Milano, Italy and M.B.S., Treviso, Italy. For tumour 
induction, animals were injected twice, at a 15 days interval, intraperitoneally 
with 200J.LI of emusifield (1:1 with PBS) incomplete Freund's Adjuvant. A 
single adjuvant injection or pristain oil (Sigma, ST. Luis, Missoury, U.s.A.), 
following the standard protocol, and PBS as control, were also evaluated for 
tumour induction. Procedures involving animals and their care were 
conducted in conformity with the institutional guidelines that are in 
compliance with national and international policies (EEC Council Directive 
86/609, OJ 1385,1, Dec.12 1987; NIH Guide for the care and use of 
Laboratory Animals, NIH Publication No. 85-23, 1985). 
2.2 HistoloKY and Electron Microscopy 
After two weeks of the second injection mice were sacrificed. 
Tumours were surgically removed and fixed in 10% formalin in PBS and 
paraffin embedded. Sections of 4-6 J.Lm thickness were cut and stained with 
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haematoxylinl eosin. Sudan III staining (ICN Biomedicals S.r.l., Milano, Italy) 
was performed on cryostat sections of lymphangioma following the 
standard method. Sections were examined at the optical microscope and 
photographed. For electronmicroscopy, tumour samples were fixed with 
2.5% glutaraldehyde in O.lM sodium phosphate buffer, pH 7.3 for 1 hour at 
4°C. Post-fixation was performed in 1% osmium tetroxide (Sigma) in 0.1 M 
cacodylate buffer, pH 7.3. Specimens were dehydrated up to 100% ethanol, 
treated with propylene-oxide and embedded in Araldite (Fluka, 
Switzerland). Polymerization was carried out at 60°C for 3 days. Ultrathin 
sections were cut with an Ultracut ultramicrotome (Reichert Jung, Germany). 
Grids were stained with uranyl acetate and lead citrate, and examined with a 
JEOL-JEM 100S transmission electron microscope. Histological specimens 
were also obtained from Araldite embedded samples. Semithin sections of 1 
nm thick were cut with the ultramicrotome and stained with 1% toluidine 
blue in 0.5% sodium carbonate at 90°C, and observed with a Zeiss Axiophot 
microscope. 
The preparation of the histological sections was done in collaboration 
with Prof. Giorgio Stanta of the Istituto di Anatomia Patologica, Universita 
degli Studi di Trieste. The electron microscopy specimens were done by Dr. 
Marina Zweyer of the Dipartimento di Morfologia Umana Normale, 
Universita degli Studi di Trieste. 
2.3 Immunohistochemistry 
Lymphangioma fragments were frozen in liquid nitrogen and stored 
at -20°C; 8-10 pm cryostat sections were fixed in acetone and 
64 
immunostaining was performed as described (291). Sections were stained 
with the rat anti-mouse CD31/PECAM mAb Mec 7.46 (kindly provided by 
A. Vecchi, Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy), a 
biotinylated rat anti-mouse ICAM-2 mAb (Pharmingen), and a biotinylated 
rat anti-mouse ICAM-l/CD54 mAb (Jackson, West Grove, PA, U.S.A.). Anti-
Flt-4 and anti-Flk-l were affinity-purified rabbit polydonal antibodies (Santa 
Cruz). As second antibody, a biotin-conjugated goat anti-rat (Vector 
Laboratories) or a biotin-conjugated anti-rabbit IgG (Dako) was used. 
Reactions were developed with Fast Red (Sigma) after incubation with 
alkaline-phosphatase-conjugated Streptavidin (Boehringer Mannheim). 
2.4 Preparation of Pituitary extract <Endothelial Growth Factor> 
All the procedure was carried out at 4°C. The hypothalamus area was 
excised from fresh bovine brain, washed in NaCI O.IM and homogenized 
(IKg of hypothalamus/l.25 1 NaCl). The mixture, pH of 6.8, was kept in 
agitation for at least 2h. After centrifugation (13800g 40min.) the supernatant 
was collected and streptomycin sulphate (Sigma) (0.5 gr./I00 ml) was added. 
The mixture was kept in agitation overnight, centrifuged (13800g 40min.) 
and aliquoted in eppendorf tubes. Storage was done at -804°C. Different 
dilutions of the pituitary extract were tested on HUVEC cells and routinely 
used 1:200 dilution in fresh medium. 
2.5 Primary Cell Culture 
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After explantation, tumours were mechanically disrupted and washed 
in RPM! 1640/Hepes medium (Life Technologies Ltd., Paisley, U.K.), 
supplemented with 100 U/ml penicillin, 0.1 mg/ml streptomycin (Sigma), 
and incubated for 30 min. at 37°C in PBS containing 0.5 mg/ml Collagenase 
H (Boehringer Mannheim GmbH, Mannheim, Germany); digestion was 
stopped by washing with medium containing 10% foetal calf serum (FCS). 
Cells were centrifuged at 700g, resuspended in medium supplemented with 
antibiotics, 20% FCS, 1 mM sodium pyruvate, 2 mg/ml glutamine, 100 
mg/ml heparin (Sigma) and 30 J,1g/ml endothelial cell growth supplement 
(ECGS, Sigma), and plated in dishes previously coated with 1% gelatin 
(Sigma) in complete medium. Cells were maintained in culture until the 
monolayer was achieved, then treated with trypsin and replated in complete 
medium without heparin and ECGS, supplemented with 10% of their own 
conditioned medium. 
2.6 Lymphangioma cells trasplantation 
Cells were harvested by typsinization, washed in PBS and diluted to 
1xl06 cells per ml in PBS. Cells were injected intraperitoneally in syngenic 
mice (Balb/c, Swiss); three to eight weeks after injection the mice were 
sacrificed and the peritoneal area evaluated. 
2.7 Cell lines and transfection 
The murine myeloma SP20 (ATCC, Rockville, USA) was maintained in 
RPMI 1640 supplemented with 10% FCS, 2 mg/ml glutamine, penicillin (100 
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U /ml), streptomycin (100 Jlg/ml) and 1 mM sodium pyruvate. The NIH3T3 
murine fibroblast (ATCC, Rockville, USA) and the murine 
monocyte/macrophage J774A.1 cell lines were maintained in DMEM with 
10% FCS, 2 mg/ml glutamine and the same antibiotics listed above. The 
Chinese Hamster Ovarian (CHO) cell line (ATCC, Rockville, USA) was 
growth in <x-MEM medium supplemented with 10% serum and the same 
components described for DMEM. 
CHO transfection was performed by electroporation. 2 x 106 cells 
were washed, resuspended in 500 J.1l cold PBS, mixed with Bgm linearized 
plasmidic DNA (10 Jlg in 20 JlI H20) and electroshocked with one pulse using 
the Bio-Rad Gene Pulser at 250 volts and 960 JlF. After 5 min. on ice, the cells 
were washed twice, suspended in 30 ml medium and seeded into three Petri 
dishes (100 mm diameter) for selection and cloning by G-418 (Genetic in, Life 
Technologies, Inc., Gaithersburg, MD) at a concentration of 500 Jlg/ml in 
culture medium. Transfected cells were cultured for three weeks for colony 
formation. Colonies were separately harvested and positive clones were 
identified by western immunoblotting. 
2.8 6-Galactosidase staining 
For detection of ~-gal activity in mice tissues, cryocut tissue slides 
were fixed in 2% gluteraldehyde solution for 5 min. at 4°C, washed with PBS 
three times for 10 min. and later incubated in stain solution (8.4 mM KCI, 
ImM MgC12, 3mM K4FE(CN)6, 3mM K3Fe(CN)6, 3% 5-bromo.4-clore-3-
indolyl ~-D-galactopyranosyde (X-Gal) overnight at 37°C. 
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This experiment was performed in Haartman Institute, University of 
Helsinki, Finland, by Lotta Iussila. The heterozygous knock-out Flt-4+/-
mouse, which contain a p-galactosidase expression cassette under the control 
of the Flt-4 gene promoter used in the assay, is a animal model kindly 
provided and developed by Kari Alitalo in collaboration with Daniel J. 
Dumont (74). 
2.9 RNA extraction and RTI PCR analysis 
Umbilical cords were obtained from pregnant mice at 18 days 
postcoitum. Aortas were collected from adult animals and the adventitia 
tunica was surgically separated from the media and intima. Total RNA was 
extracted from the tumour, from mouse normal tissues and mouse cell lines 
with a standard method (50). 
For RT IPCR, a single reverse transcription reaction was performed 
on each RNA sample using 1 llg of total RNA and the Gene Amp RNA-PCR 
kit (Perkin Elmer Cetus, Norwalk, CT, U.S.A.) with oligo-dT as primer. Each 
reverse transcription reaction was divided into aliquots and PCR 
amplification was performed with sets of primers specific for defined regions 
of the different transcripts as reported in Table II). 
In order to perform RT IPCR analysis of chemokines expression, total 
RNA was isolated from different tumours using the acid guanidinium 
thiocyanate procedure. Aliquots from each preparation were mixed and two 
micrograms of the total RNA mixture were reverse transcribed following 
the above protocol. PCR amplification was performed with sets of primers 
specific for the different chemokine coding regions as reported in table II. 
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For each sample thirty five cycles of PCR were done under the following 
condition: 1 min. denaturation at 95°C, 1 min. annealing at 58°C and Imin. 
extension at 72°C. The identities of all PCR products were confirmed by 
Southern blot analysis using as probes [32P]-end labelled oligonucleotides 
specific and internal to the amplified fragments (TAB. II). Oligonucleotides 
were purchased from Primm s.r.l., Milano, Italy. 
2.10 Southern Blot analysis 
Five microliters of each PCR fragments were loaded and separated in 
1-1.5% agarose gel and overnight transferred to nylon membranes 
(Hybond-N, Amersham, UK) by Southern methods. After transfer, DNA 
was U.V. cross-linked to membrane. Filters were prehybridized for 1h at 
42°C with SET 2X/ 0.25% v /v skimmed milk and hybridized in the same 
solution for 4h at 42°C with the specific internal oligonucleotides ['Y_32P] ATP 
labelled. The reaction for 50 ng of oligonucleotides was carried out in a total 
volume of 50J.lI in presence of 10 units of T4 Polynucleotide Kinase (BioLab, 
U.K.) and 20 J.lCi [,y_32P] ATP (Amersham U.K., Ltd.). Samples were incubated 
at 37°C for 30' and radiolabelled fraction was purified from unincorporated 
nucleotides by in Nick-Column (Pharmacia, LKB) filtration. After 
hybridization filters were washed twice in SET 2X/ D.l % SDS, twice in SET 
lX/D.l %SDS and once in D.lX SET/D.l% SDS for 15 min. between 42°C and 
48°C and autoradiographed o.n. at -70°C using X-O-Mat "5" (Kodak) 
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CDNA Primers Probes 
VEGF F 5'-TCCGAAACCATGAACTTTC-3' 5'-CTCCAACCATGCCAGTGGT-3' 
586bp R 5'-TGGCTCACCGCCTTGGCT-3' 
Flk-l F 5'-GACAAGACAGCGACTTGC-3' 5'-ACCTTGGAGCATCTCATCTG-3' 
654bp R 5'-AATTGTGTATACTCTGTCA-3' 
Tie-l F 5'-GTGCTGGTCGGAGAGAACCTGGCCT-3' 5'-ACTACAGCGTTT AT AC-3' 
430bp R 5'-AGGTGAAGTTCTCAAACAGCGACAT-3' 
Tie-2 F 5'-AGTTGGTGAAAAACTACATAG-3' 5'-AGTGATGTCGGTCCTAT-3' 
427bp R 5'-GGTAAACTTCTCATACAGTGTGGT-3' 
Flt-4 F 5'-TTGGCATCAA TAAAGGCAG-3' 5'-CAGCGAGCACCGTGCCCT-3' 
788bp R 5'-CTGCTGGGTGTACACCTTA-3' 
VWF F 5'-TGGTCCGCTATGTCCAAGGT-3' 5'-AGTCAGCTACCTCTGTGACCT-3' 
360bp R 5'-TCTTA TTGAAGTTGGCTTCA-3' 
GAPDH F 5'-ACATGTTCCAGTATGACTCT-3' 5'-GAGTATGTCGTGGAGTCT-3' 
570bp R 5'-TGCCTTCCGGTACGGTCAC-3' 
RANTES F 5'- GGTACCATGAAGATCTCTGCA-3' 5'-AGGAGTA TTTCTACACCAG-3' 
293bp R 5'-AAACCCTCTATCCTAGCTCAT-3' 
JE F 5'-ACCACCATGCAGGTCCCTGT-3' 5'-AACCTGGATCGGAACCAAAT-3' 
464bp R 5'-GAGTCACACTAGTTCACTGT-3' 
IP-lO F 5'-CCCCATCAGCACCATGAAC-3' 5'-ATAGGGAAGCTTGAAATCAT-3' 
331bp R 5'-GCTTCACTCCAGTT AAGGA-3' 
KC F 5'-GTACCATGATCCCAGCCAC-3' 5'-AACATCCAGAGCTTGAAGGT-3' 
312bp R 5'-GTCTTCTTTCTCCGTTACTTG-3' 
MIP-2 F 5'-ACTTCAGCCTAGCGCCATGG 5'-AACTGCGCTGTCAA TGCCTG-3' 
303bp R 5'-AGGTCAGTTAGCCTTGCCTT-3' 
CtO F 5'-CAGGAGGATGAGAAACTCCA-3' 5'_ TATGCCACACAGATCCCATG-3' 
362bp R 5'-CTTCTCAAGCAA TGACCTTG-3' 
Lpnt F 5'-CTCAGCCATGAGACTTCTC-3' 5'-AAAGCAGCGATCAAGACTGT-3' 
360bp R 5'-TGGAGGCTGTTACCCAGTCA-3' 
BLC F 5'-AGAATGAGGCTCAGCACAGC-3' 5'-ATAGATCGGATTCAAGTTACG-3' 
314bp R 5'-TAGTGGCTTCAGGCAGCT-3' 
6Ckine F 5'-ATGGCTCAGATGATGACTCT-3' 5'-AGCCTGGTCCTGGCTCTCTGC-3' 
409bp R 5'-TACTGGGCTATCCTCTIGA-3' 
MIG F 5'-TGCCATGAAGTCCGCTGTTC-3' 5'-ATAAGGAA TGCACGATGCTC-3' 
398bp R 5'-AAAGTAA TGGTCTCTTATGTAG-3' 
EXODUS F 5'-AACTCAACCACAATCATGGC-3' 5'-GACCAGGCTCTCTGCATC-3' -
412bp R 5'-GCTATCCTCTTGAGGGCTGT-3' 
MIPt-(X F 5'-AACATCATGAAGGTCTCCAC-3' 5'-TCATCGTTGACTA TTTTGAA-3' -
294bp R 5'-CCAAGACTCTCAGGCA TTCA-3' 
MIP1-~ F 5'-ACACCATGAAGCTCTGCGT-3' 5'-AGACCAGCAGTCTTTGCTCC-3' -
293bp R 5'-CGCTGGAGCTGCTCAGTTC-3' 
MIPl-y F 5'-TAAGAAGATGAAGCCTTTTCA-3' 5'-ACTCTTCAGA TTGCTGCCTG-3' 
390bp R 5'-TCTCTAAAGCAAATGTTATTGT-3' 
Table II: Nucleotide sequences of primers used for RT /PCR analysis and Southern Blot analysis. In 
the first column are indicated the transcripts of interest and the expected size of amplified 
fragments. In second column are reported forward (F) and reverse (R) primers for PCR 
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peR amplification. In the third column are indicated the oligonucleotides used as 
probes in Southern blot analysis of the transcripts. 
2.11 Cloning and Sequencing 
PCR fragments obtained by amplification of lymphangioma cDNA 
were cloned in pGEM -T Easy vector (Promega, Madison; WI, USA) 
following the manufacturer's recommendations, and used to transform E. 
coli strain DHS-a.. At least three positive clones from each transformation 
were sequenced using the T7 Sequencing kit (Pharmacia LKB ). 
The CIO amplified fragment was purified from I % agarose gels by 
electroelution. The recovered DNA fragment was blunted and 
phosphorylated by treatment with Klenow and Kinase enzyme (BioLab, UK) 
and ligated in the SmaI site of PUCl8 (Pharmacia LKB, Uppsala, Sweden). 
lp,g of Puc 18/CIO construct was EcoRI/Hindill digested (BioLab, UK), the 
374 nucleotides fragment purified and subc10ned into the EcoRI/Hindill 
cloning sites of the pcDNA3 vector (Invitrogen, CA, USA). Maxi preparation 
of the plasmid pcDNA3/CIO was obtained with the Quiagen plasmid kit 
(Quiagen, Germany) and the concentration determined by 
spectrophotometry. 
2.12 N orthem Blot analysis 
Total lymphangioma RNA (20 ~g/ sample) was separated by 
electrophoresis in denaturing 1% agarose gel containing 6% formaldehyde, 
transferred to nylon membranes (Hybond-N, Amersham, UK) by overnight 
capillary blotting in 20 X sse and fixed with UV light. The filters were 
71 
hybridized with different probes generated by convenient restriction 
enzyme digestion of the PCR amplified fragments cloned in pGEM-T Easy 
Vector (Promega, Madison, WI, USA). The size of probes are reported in 
table II. Probes were labelled with [a_32p] dCTP (Amersham, UK) using the 
oligolabelling kit (Pharmacia, LBK). 
Hybridizations were carried out overnight at 50°C in 5X SSPE/O.5% SDS/5X 
Denhardt's/ 50% formamide/ 100 mg/ml salmon sperm DNA. Filters were 
washed in 2XSSC/ 0.1% 50s at 50°C, 60°C and 70°C for 30' and 
autoradiographed overnight at -70°C using X-O-Mat "5" (Kodak). 
Total RNA of mouse skeletal muscle cells was included as control. 
2.13 In situ Hybridization 
In situ hybridizations were performed basically as described by 
Komminoth et al. (154) with modifications. 5 Ilm thick, formalin fixed, 
paraffin-embedded tissue sections were placed on Superfrost Plus-treated 
slides (Fisher Scientific). Tissue sections were deparaffinized, hydrated and 
permeabilized with 0.5-0.2 Ilg/ml proteinase K for 30 min. at 37°C, and 
prehybridized in hybridization buffer containing 50% formamide, 50 mM 
HEPES, 5X Denhardt's solution, 4X SSC, 250 Ilg/ml denatured herring sperm 
DNA and 5 mM EDTA, pH 8.0 for 2h at 42°C. Hybridization was performed 
overnight at 56°C in a humidified chamber (5-10 ng of digoxigenin-Iabeled 
RNA probe in 200 J.Ll of hybridization buffer/slide). As a negative control, 
sections were treated with RNAse A prior to prehybridization, and a second 
negative control was performed using the corresponding sense RNA as a 
probe. All the templates were obtained by amplification of lymphangioma 
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cDNAs with the oligonucleotides above described (table II), inserted into the 
pGEM-T plasmid vector (Promega) linearized and transcribed with SP6 RNA 
polymerase or 17 RNA polymerase (Promega) for the synthesis of the 
antisense and sense RNA probes, respectively (TAB. III). RNA probes were 
labelled with DIG-UTP using the Dig RNA labelling mix (Boehringer 
Marmheim). 
After hybridization, unbound probe was digested with RNAse A (20 
Jlg/ml) for 30 min. at 37°C. Post-hybridization washes were all performed at 
37°C and consisted of two washes in 2X sse, two in 0.2X SSC, and one in 
O.IX SSC (each for 15 min.). The hybridization signal was detected according 
to the instructions of the Dig Nucleic Acid Detection kit (Boehringer 
Mannheim), using Fast Red as a substrate of alkaline phosphatase. The slides 
were counter-stained with Harris solution (Sigma), and mounted with 
glycerol/phosphate-buffered saline (50% v Iv). 
TEMPLATE Res. Enzyme!S Res.Enzyme! A Probe Size 
ICAM-l Sall 431bp 
ICAM-l Nco I 431bp 
FLT-4 Sma I 468bp 
FLT-4 Sma I 217bp 
MIG-l Sal I 398bp 
MIG-l Nco I 398bp 
JE SpeI 504bp 
JE Hpal 436bp 
Lptn Spel 462bp 
Lptn Nco I 441bp 
C10 EcoRI 374bp 
C10 Hind III 374bp 
TableIII: peR fragments cloned in PGEM-T easy vector are linearized in order to 
synthetize sense and antisense RNA probes. 
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2.14 Western Immunoblotting 
Extracts of lymphangioma or cultured cells were prepared by 
homogenization in lysis buffer (50 mM Tris-HCI, pH 7.5, 150 mM NaCI, 5 
mM EDTA) with protease inhibitors PMSF (1 mM), aprotinin (10j.1g/ml), and 
leupeptin (10 j.1g/ml) (all from Sigma Chemical Co.). Immunoprecipitations 
were performed by incubating the lysates with rabbit-anti mouse Flt-4 or 
rabbit anti-mouse Flk-1 antibodies, followed by addition of 50 j.11 of Protein-
A Sepharose (Pharmacia Biotech, Uppsala, Sweden). Precipitates were 
washed in RIPA buffer (150 mM NaCI, 1% NP-40, 0.5% DOC, 0.1% SDS, 50 
mM Tris-Hcl pH 7.5), eluted with 0.1 M Glycine HC} pH 2.5 and neutralized 
with 10 j.111M Tris HCI pH 8.0. Aliquots were run on an reducing 7.5% SOS-
PAGE, blotted onto Hybond ECL nitrocellulose membrane (Amersham 
International, Little Chalfont, U.K.) and reacted with the same antibodies, 
followed by horseradish peroxidase-coupled anti-rabbit Ig antibody 
(DAKO). Treatments with recombinant N-glycosilase F (PNGase f) were 
done according to the protocols provided by the manufacturer (New 
England BioLabs Inc., Beverly, MA, U.S.A.). Detection was performed using 
the ECL kit (Arnersham International) and membranes were exposed to a 
Kodak Biomax film for 1min. 
Aliquots of the same immunoprecipitated samples were incubated 
with an irrelevant antibody (goat anti-human IgE(E), Kirkegaard &Perry 
Laboratories, Gaithersburg, MA, U.S.A.), used as negative control. 
Supernatants of different pcDNA3/C10 transfected CHO clones were 
collected and the same inhibitors listed above were added. The supernatants 
were cleared by centrifugation at 10000g for 15 min. at 4°C. Subsequently, 
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50111 of each supernatant were subjected to 12% SD5-PAGE and Western 
blotted. The membrane was incubated with a 1: 100 dilution of goat anti-
mouse C10 (Sigma), followed by horseradish peroxidase-coupled anti-goat 
Ig antibody (DAKO). The bound antibodies were detected by EeL. 
2.15 Separation of Murine Haemopoietic Subpopulation 
For isolation peripheral blood neutrophils and lymphocytes, blood 
was collected from the retro-orbital plexus of CD1 mice 0 acKson 
Laboratories, Milano, Italy) into pipettes containing EDTA anticoagulant. 
Blood was then incubated with an equal volume of 3% dextran in 0.15 M 
NaCl. After erythrocytes sedimentation, the leukocyte-rich plasma was 
collected and washed twice with PBS/O.5% BSA (Sigma). Cells were 
resuspended in 2 ml PBS/O.5% BSA and layered over a five-step 
discontinuous Percoll 9% NaCI gradient (Pharmacia, LKB), as previously 
described (276) . After centrifugation at 500g at 20°C for 20min., the cells 
were banded at the surfaces of the gradient densities, and fractions 3 and 5 
were collected separately. This procedure resulted in a preparation greater 
than 95% of neutrophils from fractions 3 and 5 and a preparation greater 
than 95% of lymphocytes from fraction 1. Cell viability was >98% as assessed 
by trypan blue dye exclusion. Harvested cell were washed twice and 
suspended in PBS/O.5% BSA, at 2x1()6 cells/ml. 
For isolation of resident peritoneal macrophages. mice were killed by 
cervical dislocation and the peritoneal cavities were washed out with 7-10 ml 
PBS. The harvested cells were then washed twice and resuspended in 2ml 
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PBS/O.5% BSA. Cell suspension was then layered over 4ml Percoll 
suspension of 1.0830±0.0003 density and osmolitic value of 310 2m OSM. 
After centrifugation at 400g for 20min. at 20°C, the cell ring formed at the 
PBS/Pecoll interface was collected, washed twice and resuspended in PBS 
containing 1% BSA. The resulting cell suspension contained >95% 
macrophages as assessed by morphology and peroxidase-staining, and cell 
viability was >98% as determined by trypan blue exclusion. 
Mouse peritoneal neutrophils were isolated from COl 8-12 weeks old 
mice after intraperitoneal injection of 3% thioglycolate broth (BBL 
Microbiology System, ockeysville, MD). 4h later, peritoneal cells were 
harvested in 7-10 ml PBS (68). Separation of neutrophils from the peritoneal 
exudate was performed by using a Percoll gradient. Peritoneal cells 
suspended in 2ml PBS/O.5% BSA were layered over 4ml Percoll (with density 
and osmotic value above reported). The gradient was centrifuged for 20 min. 
at 400g at 4°C. The resulting cell pellet was washed twice with PBS and 
neutrophils were tested for purity by examination of eosin haematoxylin 
stained cytospin preparations. All neutrophil preparations were >95% pure. 
2.16 Separation of human neutrophilic polymorphonuclear cells 
Human PMN were isolated from acid-dextrose (ACD)-anticoagulated 
blood by Ficoll-Hypaque (Nycomed Pharma AS, Oslo, N), gradient 
centrifugation, 3% dextran (Pharmacia) sedimentation and hypotonic saline 
lysis of contaminating erytrocytes (31). The entire procedure was conducted 
at 4°C. Purified PMN were suspended in PBS containing 1% BSA. 
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2.17 Chemotactic Assay 
The in vitro migration of leukocytes was assessed in a 24-well 
transwell chamber with a 5 or 1.2 Jlm pore polycarbonate Transwell culture 
insert (Costar, Cambridge, MA) as described previously (27). Briefly, 
leukocytes were suspended in RPM! 1640 medium containing 10% fetal calf 
serum, at 2.5x106 cells/ml. The lower wells were filled with 600 JlI of 
lymphatic endothelial cells conditioned medium (LCM) or control medium 
containing 1% Zymosan activated serum (ZAS), 25 ng/ml MlP-
lex. (Genzyme, Ma, USA) or C10 transfected CHO cells supernatant. The 
upper wells were filled with 100 JlI of cell suspension. Assay were carried out 
at 37°C for 30 min. for neutrophils, 1h for macrophages and 3h for 
lymphocytes. Cell migrated into the lower chamber were then harvested 
and counted in a ZBI Coulter Counter (Coulter Electronics LDT, Luton, UK). 
The results were expressed by mean (+ / -) number of migrating cells in five 
or more random high-power fields tested in triplicate. 
Significance of the value was determinate by paired T-Test (*p<O.OOOl). 
2.18 ZAS Preparation 
5 mg of lyophilised Zimosan (Sigma), were resuspended in 1 ml PBS 
and boiled 5 min. After centrifugation, 2000 rpm 10 min., the pellet was 
resuspended in 125JlI PBS and added to fresh serum with a proportion of 1 :4. 
TIUs solution was incubated 30 min. at 37°C in order to activate the 
complement present in the serum and then centrifuged 12000 rpm 5 min .. 
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The zymosan activated serum (ZAS) was recovered and added at 1 % into the 
medium. 
Chemotactic assays were performed in collaboration with Dr. Aldo 
Dobrina and Dr. Elena Vecile of the Dipartimento di Fisiologia e Patologia, 
Universita di Trieste. 
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Chapter 3 
RESULTS 
LYMPHANGIOMA CHARACTERIZATION 
3.1 Induction and histopathology of intraperitoneal tumours 
The intraperitoneal injections of incomplete Freund's adjuvant into 
mice induced the development of multicentric and clearly delineated white 
solid masses, with the histological appearance of lymphangiomas. These 
lesions, varying in size from 5 to 50 mm2 were localized in the peritoneal 
cavity along the thoracic duct, on both abdominal surfaces of the diaphragm 
and on the upper surface of both lobes of the liver (Fig. 12a). In some cases, 
they were also observed on the surface of the spleen. 
We have tested more than 100 Balb/c mice and found that the lesion was 
induced in all (100%) injected animals. Smaller masses were evident even 
when the animals were injected with a single dose of the adjuvant. Although 
the lesion size was usually slightly larger in female mice, we did not observe 
any other difference related to sex or age. Other strains of mice such as 
AS/N, C57 black, and Swiss were also treated in order to exclude the 
possibility that lesion formation was related to the genetic background. In all 
three strains the same efficiency of response (100%, 15 animals each) was 
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observed even though the sizes of the lesions were usually smaller than in 
Balb / c mice. Furthermore, we observed that pristane, a mineral oil widely 
used to establish ascitic growth of myeloma or hybridoma cells (161) was 
also effective in inducing the development of peritoneal masses. 
The white colour of the masses suggested that the lesions were caused 
by developing lipomas; in order to verify this hypothesis Sudan III staining 
was performed on cryocut sections. Actually, as indication of lipids presence, 
• the staining was strongly positive, but the microscopical analysis revealed 
that the lesions were not formed by adipocytes. The lipidic material was not 
stored in adipocytes liposomas, but in lumina surrounded by a variable 
number of cells, as indicated by the nuclei pointed out (Fig. 11). 
Histopathological analysis of the lesions after haematoxylin/ eosin 
staining revealed the presence of endothelial cells surrounding empty 
lumina. Various levels of vascular development were present. Observed cells 
showed intracytoplasmic vesicles of different sizes and fused to 
neighbouring cells forming vessel-like lumens (Fig. 12c, d). The lesions were 
not infiltrated with either erythrocytes, lymphocytes or platelets. However, 
recruitment of granulocytes was frequently observed in the region of the 
liver close to the lesion (Fig.12b). No evidence of direct infiltration of the 
organ parenchyma was observed. On the surface of the liver, tumour 
growth was restricted to a region under the Glisson's capsule, with no 
infiltration into the hepatic parenchyme (Fig.12b-d) or metastasis. When the 
mice were sacrificed six or eight months later, in absence of stimuli, no 
progression, but still persistence of the lesion was observed. Only in a single 
case the described lesion was accompanying a neoplastic formation detected 
in an axillo lymph node. 
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Figure 11. Sudan III staining of lymphangioma section. 
Different magnification (a-b) of a frozen section of lymphangioma lesion 
stained with Sudan Ill, a staining specific for the identification of lipids. Cell 
nuclei are stained in purple, cytoplasma in grey. Red spots identify different 
size extracellular areas of lipids accumulation, corresponding to the lumina 
revealed in the lesion as seen in Fig. 12. 
Figure 12. Anatomical localization, histological analysis and electron 
microscopy of lymphangioma. 
(a) Peritoneal cavity of a Balb / c mouse showing the white plaques of the 
lymphangioma tumour growing on the peritoneal surface of the diaphragm (black 
arrow) and on the surface of the liver (white arrow). (b-d) Histological section of 
the liver lesion, stained with hematoxylin and eosin (b, c) or toluidine blue (d). It 
is apparent that the tumour grows under the Glisson's capsule (GC) without 
infiltrating the hepatic tissue. On the boundary between the tumour (T) and liver 
(Li), a collection of leukocytes is present without evidence of tissue or cell necrosis 
(b). At higher magnifications (c-d) vacuolated cells and fused cells at different stages 
of lumen formation can be seen. Vesicles of different sizes, in some cases confluent 
(d) are present. e, Electron microscopic picture of a single lymphangioma cell 
containing two lumens with irregular borders. Cross and longitudinal sections 
corresponding to intermediate filaments are also evident. N, nucleus; L, lumen (Bar, 
Inm). 
Ultrathin sections of the tumour, analysed by transmission electron 
microscopy, showed the characteristic formation of lumens surrounded by 
endothelial cells. Often, a single endothelial cell was found participating in the 
formation of more than one luminal cavity (Fig. 12e). Several vesicles, 
especially the ones with a smaller diameter, showed an irregular outline. In 
the cytoplasm a number of high density granules were present, while no 
Weibel-Palade bodies, the characteristic organelles where von Willebrand 
Factor (vWF) is stored (296) could be identified. Bundles of collagen fibrils, 
revealed by their characteristic banding (data not shown), were observed in 
different orientations in the extracellular compartment. 
Considering that: liThe word tumour means literally an abnormal 
swelling. However, in the language of modem medicine, the word assume 
the meaning of a lesion resulting from the autonomous abnormal growth of cells 
which persist after the initiating stimulus has been removed." (287), it will be 
correct think of the described lesions as a tumour of (lymphatic) endothelial 
cells. 
3.2 In vitro propagation of tumour derived cells 
The lymphangioma tumours could be easily explanted and separated 
from the surrounding tissues. The endothelial cells recovered after treatment 
with collagenase grew in vitro (Fig.13) in an anchorage dependent manner: 
the dishes had to be coated with gelatin for the successful establishment of 
the primary cultures. When cultivated in the presence of bovine vascular 
endothelial growth factor or a crude bovine pituitary extract, the cells 
81 
a 
b 
c 
Figure 13. Primary culture of lymphangioma derived cells. 
Phase contrast images of cells after 48hrs of plating (a), at confluence after 
approximately 10 days of colture and after three passages (c), where spontaneous 
formation of elongated structures can be seen. The culture is performed in dishes 
previously coated whith 1% gelatin in complete medium. Initially (a-b) cells are 
growing in complete medium supplemented with 30mg/ml of endothelial cell 
growth supplement (EeGS) or in presence of pituitary extract (1:200 in medium). 
Replated cells were cultured in complete medium supplemented with 10% of their 
own conditioned medium. Lymphatic endothelial cell conditioned medium is 
indicated as LCM. 
proliferated, albeit at a low rate with a doubling time of about 48-60 hours, 
reaching confluence in eight to ten days. At this stage, the lymphangioma 
cells showed a classical cobblestone morphology (Fig. 13a) and further cell 
proliferation was contact inhibited. After the third/fourth passage, cellular 
growth slowed down and the capacity to reach a high cell density was lost. 
An increased number of cytoplasmic vacuoles was also evident in these cells. 
After a period of two to three months, the cells entered a 
quiescence/ senescence state and died. At this stage, cellular morphology 
changed drastically with cells becoming multinucleated with a large 
cytoplasm. Nevertheless, during the initial period of culture (usually after 5 
to 20 days) spontaneous formation of characteristic vessel-like structures was 
observed, starting from the lengthwise pairing of a few cells (Fig. 13b, c). The 
capacity of primary cultures of lymphatic endothelial cells to form vessel-like 
structures has been shown for bovine cells from the thoracic duct (210, 229). 
3.3 Trasplantation of lymphansioma cells 
In order to evaluate the growth potentiality of the lymphatic 
endothelial cells in syngeneic, untreated host, transplantation experiments 
were done. Balb / c and Swiss mice were sacrificed and analysed 
macroscopically after three-eight weeks from the intraperitoneal injection of 
lymphangioma cells. Any animal didn't shown evidence of tumour 
formation neither in the injection site, nor on organs surfaces in the 
peritoneal area. 
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3.4 Expression of endothelial markers 
To further characterize the tumours we examined the expression of 
endothelial cell markers such as the VEGF-receptor Flk-l and other receptor 
tyrosine kinases Tie-I, Tie-2 and Flt-4 (ISS, 238, 72, 88) and the intracellular 
vWF. In addition, the expression of the vascular endothelial growth factor 
(VEGF) (147) (171) was investigated in the lesions. The analysis was by 
means of specific RT /PCR of defined regions of the corresponding mRNAs, 
followed by hybridization with probes specific for the amplified segments. 
As a control of normal mouse endothelium, we used mRNA extracted from 
the umbilical cord and the vascular endothelium of the aorta, as well as from 
the adventitia of the aorta which is rich in lymphatic vessels and does not 
contain blood vessels. Other controls included mRNA from adult mouse 
liver, from NIH 3T3 cells and from the myeloma Sp2/0. A single reverse 
transcription reaction was divided in equal aliquots that were subsequently 
amplified by PCR with the corresponding specific oligonucleotides. Negative 
controls were included for all amplifications. 
As shown in Figure 14a, the VEGF mRNA was expressed by the 
lymphangioma, aorta and Nll-I-3T3 and Sp2/0 cells, but little or no VEGF 
mRNA was detected in the adventitia or the umbilical cord. The amplified 
bands corresponded to two previously described alternatively spliced VEGF 
isoforms differing by 72 nt, corresponding to the exon 6 (285). The identities 
of these bands were confirmed by sequencing (not shown). The longer form, 
which encodes a mature protein of 188 aa was expressed more abundantly 
than the 164 aa form in the lymphangioma. The major mitogenic receptor 
for VEGF, Flk-l, was expressed in lymphangioma, umbilical cord and aorta, 
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Figure 14. RT/PCR analysis of Expression of Endothelial Markers. 
Each panel shows autoradiograms of hybridizations with probes specific 
for the amplified segments of mRNA, as described in Matherials and 
Methods (sections 2.8). Sizes, in base pairs (bp), of the different amplified 
fragments are indicated on the left. For each RNA sample, a single reverse 
transcription reaction was carried out and equal aliquots were used for the 
different peR amplifications. a-g panels correspond respectively to: a) 
Vascular Endothelium growth Factor (VEGF), b) Fetal liver gene kinase-l 
(FLK-l), c-d) Tunica interna endothelial cell kinase -1 (Tie-I) and -2 (Tie-
2), e) fms-like tyrosine kinase gene-4 (Flt-4), f) von Willebrand Factor (vWF) 
and g)glyceraldehyde-3-phosphate-dehydrogenase (GAPDH). 
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Figure 15. Immunohistochemistry and in situ hybridization of 
lymphangioma sections. 
Analysis of endothelial markers was perfonned on frozen sections of lymphangioma 
by immunohistochemistry (a). Slides were incubated with antibodies for 
PECAM/ CD31 and ICAM2/ CDI02. As a second antibody a biotin-coniugated goat 
anti rat was used. The reaction was developed with Fast Red and slides counterstained 
with hematoxylin. The control section was stained with rabbit serum. (b) Paraffin 
embedded sections were hybridized with digoxigenin-Iabelled sense and antisense 
RNA probes for lCAM-l, as indicated. The hybridization signal was detected using 
Fast Red as a substrate of alkaline phosphatase and Harris solution was used for 
counter-staining. 
but not in the adventitia (Fig. 14b). As expected, also the two control cell lines 
did not express Flk-l. The 200 kDa Flk-1 protein was also identified in 
Western immunoblottings of tumours and cultured cells (Fig. 16, lane 4 and 
5). Tie-1 and Tie-2 were expressed by the lymphangioma, but not by the 
aorta (Fig. 14c, d). The lymphangioma, as well as the adventitia and the 
umbilical cord, expressed Flt-4 (Fig. 14e), while the aorta was negative. Flt-4 
represents a unique marker of lymphatic endothelial cells since within the 
mature endothelia, it is exclusively expressed by lymphatic vessels (140). It 
should be noted that the umbilical cord and the liver contain both vascular 
and lymphatic endothelium. 
Expression of vWF was also detected in the umbilical cord and in the 
aorta, but not in the lymphangioma or adventitia (Fig. 14f). Finally, the 
presence of RNA in all samples was controlled by amplification of the 
constitutively expressed glyceraldehyde-3-phosphate-dehydrogenase 
(GAPDH) mRNA (Fig. llg). 
The expression of the endothelial cells markers PECAM/CD31, 
ICAM-1/CD54 and ICAM-2/CD102 was investigated by 
immunohistochemistry. PECAM/CD3I was positive with a heterogeneous 
staining (figure 15a), while ICAM-2/CD102 and ICAM-1/CD54 (not shown) 
were only weakly stained in the lymphangiomas. Byin situ hybridization, 
ICAM-1 was clearly positive only in the region corresponding to the tumour 
(Fig.15b) and ICAM-2 was easily detected by RT /PCR (not shown) therefore 
the weakly staining is probably due to antibody limiting specificities. 
3.5 Analysis of Flt-4 expression in the lymphangiomas 
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Expression of the Flt-4 lymphatic endothelial receptor for VEGF-C 
and VEGF-D was also investigated by Western blotting, by in situ 
hybridization and ~-gal staining of tumours induced in heterozygous knock-
out Flt-4 + / - mice, which contain a ~-galactosidase expression cassette under 
the control of the Flt-4 gene promoter. 
Western blotting of anti-Flt-4 immunoprecipitates from either 
lymphangioma tumours or tumour derived in vitro primary cell cultures 
showed the 190, 170 and 120 kDa bands (Fig. 16), which are generated by 
differential glycosylation and proteolytic cleavage of the Flt-4 polypeptide 
backbone (223) In fact, after digestion with PNGase F, which removes N-
linked glycosidic residues, the two larger Flt-4 of 190 and 170 kDa merged 
into a single band of about 130-140 kDa, while the major C-terminal 
proteolytic cleavage product of 120 kDa was reduced to 97 kDa (Fig. 16, lane 
2). The N-terminal 75 kDa product was not detected in this assay because the 
polyc1onal Abs used are directed to the C-terminus of Flt-4. The same three 
Flt-4 polypeptides were also identified in extracts from tumor derived cells 
cultured for one week (Fig. 16 lane 3). The negative control of the 
experiment is represented by samples from lymphangioma tumours or 
tumour derived primary cell culture treated as described with a goat anti-
human IgE(e). 
Tumors induced in the heterozygous knock-out Flt-4+ / - l3-gal 
transgenic mice had a number of blue l3-gal positive tumour cells (Fig. 17 a), 
although the staining was not as intense as in normal lymphatic vessels (data 
not shown). Flt-4 mRNA was also detected by in situ hybridization in a large 
number of cells within the tumour (Fig. 17 b, c). 
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Figure 16. Western Immunoblot of Flt-4 and FlK-1. 
Detection of Flt-4 (lanes 1-3) and Flk-1 (lanes 4-5) proteins by immunoprecipitation 
and western blotting from tumour or cultured cells, as indicated. PNGase F treatment 
of Flt-4 immunoprecipitates is shown on the right and relative masses are indicated 
in kDa. Negative controls are represented by samples immunoprecipitated and 
incubated with a goat anti-human IgE(£). 
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Figure 17. Flt·4 expression in lymphangioma. 
Staining for ~-galactosidase on frozen section of lymphangioma 
tumour induced in heterozygous knockout Flt-4 + / - ~-gal mice 
(a). In situ hybridization of lymphangioma paraffin embedded 
sections with digoxigenin-labeUed antisense and sense Flt-4 RNA 
probes is shown in (b) and (c) respectively. The hybridization signal 
was detected using Fast Red as a substrate of alkaline phosphatase 
and Harris solution was used for counter-staining. L, liver; T tumour. 
CHEMOKINES EXPRESSION IN LYMPHANGIOMA 
3.6 Histological Analysis 
As previously described, following induction of lymphangioma we 
performed histological analysis of the lesion. The lymphangioma lesions 
were predominantly identified on the surfaces of liver and diaphragm. In all 
samples analysed neither infiltration of cells belonging to the lesion in the 
surrounding tissues nor others signs of modification of the morphological 
features of the liver parenchyma or of the muscular structure of the 
diaphragm were observed. 
Nevertheless, when slides were eosin-haematoxylin stained, it was 
evident a remarkable presence of leukocytes in the area of the tissues 
neighbouring the lymphangioma. This observation was particularly evident 
in all histological samples in which liver fragments were analysed (Fig. 18). 
Leukocytes seemed to be infiltrating the liver parenchyma closed to 
the developed lesions and often the extension of this infiltration seemed to 
be related to tumour size. In the liver region where the cells were 
accumulated no sign of necrosis was noticed. In addition, it was not observed 
invasion of leukocytes into the lymphangioma itself. The presence of 
leukocytes was also observed in areas relatively poor of blood venules and 
far from identifiable blood vessels. These observations suggested that the 
presence of leukocytes in the tissue surrounding the lymphangioma was 
probably related to a biological property of the lymphatic endothelial cells 
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Figure 18. Identification of leukocyre recruitment by histological 
analysis. 
Different magnification (a-b) of a histological section of 
lymphangioma lesion developed on liver surface. Arrows indicate 
a massive leukocyte recruitment in the area of the tissue 
neighbouring the lymphangioma. 
Leukocytes were not infiltrating the surrounded lesion and no signs 
of necrosis is evident in the region where cells were accumulated. 
represented by chemoattractant activity due to the production of 
chemokine. 
Although the expression of chemokines by blood vessel endothelial 
cells is being extensively documented (184, 185), less information is available 
regarding lymphatic endothelial cells. This aspect could be of particular 
relevance since it is not yet established what are the signals that drive 
circulation of leukocytes into lymphatic vessels. 
3.7 Chemotactic assay on human peripheral blood PMN 
In order to verify the hypothesis that lymphatic endothelial cells are 
able to secrete chemokines, an in vitro chemotactic assay was performed on 
human PMN using culture supernatants from primary culture of lymphatic 
endothelial cells as a source of chemoattractant molecules. When conditioned 
medium from one week old lymphangioma cultures was tested on human 
cells, the results obtained were extremely promising. 
As shown in Fig. 19, data recorded from five independent 
experiments indicated a high chemotactic activity, comparable to the one 
obtained with the human recombinant IL-8 , used at the concentration of 10 
ng/ml as a positive control. 
After 30 min. of incubation, more than 45% of human PBMC was able 
to transmigrate through the gelatinised membrane to the lower chamber, 
showing the same efficiency of IL-8. Chemotaxis activity by control with 
unconditioned media was reduced to 19-22%. 
The comparison of the chemoatractant activity of the supernatant and 
the one of IL-8, that is thought to be in humans the primary regulatory 
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Figure 19. Chemotactic assay on human peripheral blood PMN. 
Effect of lymphangioma derived endothelial cells conditioned medium LCM art 
ch motactic activity of normal human peripheral blood polymorphonuclear cellg 
(PMN). The negative and positive controls are unconditioned medium (C) and IL....-
8 (10 ng/ml) respectively. Results are expressed as the percentage of input ce ll& 
migra ting into the lower chamber of a transwell filter (1.2 Jlm pore size) after 30 
min. ach histogram represents the mean of five indipendent experiments and the 
ignificancy of th value between these conditions was determinated by paired T .... 
11 s t (p<O.OOOI). 
molecule of acute inflammatory states, indicated that lymphangioma 
endothelial cells, as well as other better known models of activated 
endothelial cells (Le. HUVECs) are able to secrete chemokine thus providing 
evidence that these molecule constitute at least in part, signals for trafficking 
of leukocytes through lymphatic vessels. 
The kinetics of chemokine production by the lymphatic endothelial 
cells was next investigated using media conditioned for 48h at different 
moments from the establishment of the primary culture. The highest level of 
chemoattractant activity was recorded in cell culture derived from the 7th to 
the 10th day. After twelve days the chemoattractant activity on PBMC was 
significantly reduced. This observation indicates that in vitro chemokines 
production by lymphangioma derived endothelial cells is transient and 
probably related to the absence of appropriate stimuli. 
3.8 Screening of chemokine expression in lymphangioma derived 
In order to establish the profile of chemokines secreted by lymphatic 
endothelial cells, we investigated the expression of the different chemokines 
by means of specific reverse transcription/PeR of defined regions of the 
corresponding mRNAs. 
For this assay total RNA was obtained from lymphatic cells after 
tumour explantation or from cultured cells. 
Appropriate oligonucleotides were designed from mRNA sequences 
of mouse chemokines obtained from EMBL/GenBank/DDBJ database for 
each chemokines considered in our screening. Two primers were 
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synthesized in order to amplify the complete coding region and a third one, 
homologous to an internal sequence, for specific hybridization of the 
amplified fragments. 
During the last year the progress in the chemokines field has been 
extremely rapid with a continuous growth of the number of human and 
mouse new chemokine sequences identified. We restricted our investigation 
to verify the expression of only the better known chemokines. 
As shown in Fig. 20, the expression of eleven chemokines among the 
fourteen investigated was identified. The lymphangioma was found to 
express chemokines belonging to all three subfamilies: C-X-C or a 
chemokines (KC, IP-lO, MIP-2, BCL and Mig-I), C-C or ~ chemokines 
(Exodus, 6Ckine, RANTES, JE and ClO) and C or 'Y chemokine 
(lymphotactin). Interestingly, three well known ~ chemokines (MIP-la, MIP-
l~ and MIP-l'Y) were not detected. These chemokine are secreted by 
haemopoietic lineage cells (monocytes, lymphocytes, neutrophils, mast cells), 
but also by fibroblasts, smooth muscle cells and tumour cell lines (300, 311, 
323) MIP-l a, ~ and 'Y display a wide range of biological activities. Among 
these activities remarkable is their role in different diseases such as 
rheumatoid arthritis and their IDV-suppressive effect as recently reported 
(53). 
In most cases the correct identity of the amplified cDNA was also confirmed 
by sequencing (not shown). GAPDH fragment was amplified as internal 
control for each reaction. 
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To evaluate the relative expression level of each chemokine, the same 
amplified fragments were used as probes in Northern blot analysis of total 
lymphangioma RNA (Fig. 21). GAPDH was used as an internal control. 
Positive expression as judged by a signal in the Northern blot was 
confirmed for most but not all the chemokines that were detected by 
RT /PCR analysis. 
The hybridization signals of KC and RANTES molecules were not 
detectable even after a week long exposure, whereas all other bands shown 
in Fig. 21 were obtained after o.n. exposure. The identified signals 
corresponded to the expected sizes of mRNA of the different chemokines 
and revealed the existence of different expression levels among the 
investigated molecules. 
Once again, positive chemokines belonging to the three different 
subfamilies were identified. Mig-1 was the a-chemokine with the highest 
expression level, while JE and CI0 were the highest ones of the ~ subfamily. 
Lptn (ychemokine) resulted weekly positive. 
Fig. 20 shows amplified fragments corresponding to Exodus and 6Ckine. 
Although these molecules were described independently as two different 
chemokines (43, 123), their nucleotide sequences differ only by three 
nucleotides (position 38,41 and 194 of the cds), suggesting that 6Ckine and 
Exodus represent a polymorphic version of the same molecule. The two 5' 
primers used ended at its 3' end at nucleotide 41 and therefore were specific 
for each polymorphic version. The high homology between the two 
sequences did not permit to discriminate the relative expression levels of 
both chemokines by Northern blot analysis since the unique signal 
represented the expression of both molecules. 
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Figure 20. RT/PCR analysis of Chemokine Expression in 
Lymphangioma. 
Each lane shows the autoradiogram of hybridization with a specific 
probe for the amplificated segment of mRNA, corresponding to 
the complete cds of the investigated chemokine. Sizes of the different 
amplificated are indicated in base pairs (bp) close to the molecule 
name. Chemokines of the same subfamily are grouped togheter. 
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Figure 21. Northern blot analysis for Chemokine expression. 
Northern blot analysis on total lymphangioma RNA showing different levels of 
expression of the identified chemokines. For each chemokin transcript the 
corresponding amplified fragment [a-32p] dCTP labelled was used a hybridization 
probe. The autoradiograms shown in the figure were obtained after O.n. exposure. 
GAPDH was used as an intelnal control. Expression of KC and RANTES chemokin , 
identified by RT /PCR, was not confirmed by Northern blot analysis, while remarcable 
is the expression of CIO. Total RNA of murine skeletal muscle cells was used a 
negative control: the line indicated by GAPDH* represents the expression in this 
sample. No chemokines expression was identified in murine skel tal muscl cells 
(data not shown). 
GAPDH expression was identified in skeletal muscle cells mRNA, but 
no chemokines expression was revealed in the control sample (data not 
shown). 
Interestingly, the signal of chemokine CIa detected in the Northern 
blots indicated an extremely high expression of this molecule by the 
lymphangioma. ClO was originally identified as a transcript that is induced in 
bone marrow cells upon stimulation with GM-CSF, IL-3 or IL-4 (221, 222). 
Our observation provides the first evidence that CIa is expressed also in cells 
different from the ones of the haematopoietic lineage: the lymphatic 
endothelial cells. In addition CIa has only been reported in the mouse, no 
human homolog is known and the biological significance of this molecule is 
still not well understood. CIa is also unique among ~ chemokine because it 
contains an extra second exon encoding a 16 amino acid sequence which is 
inserted in the amino terminal region of the protein. The sequence encoded 
by this exon plays probably a key role in recognizing and activating its 
specific receptor, that has not yet been identified (23). Because of all these 
reasons, the CIa chemokine was taken into consideration for further 
investigation. 
3.9 In situ hybridization 
All the information provided by the Northern blots analysis as well as 
those reported by chemotactic assay performed with the primary culture 
supernatants, were in accordance with the hypothesis that chemokines 
secretion was a functional property of the lymphangioma forming cells. 
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However, in order to assure that chemokines production by 
lymphatic endothelial cells was a general characteristic of the most of the 
tumour cells, in situ hybridization was performed on lymphangioma 
sections using specific anti-sense and sense RNA probes (Fig. 22). 
Sequential tissue slides of lymphangioma were obtained from the 
same histological preparation that was used to perform the in situ 
hybridizations for Flt-4 and ICAM-I above described (Fig. I7b, c). 
For each chemokine subfamily we chose a molecule that m the 
previous assay showed a high level of expression: Mig-I, JE and lptn 
respectively corresponding to the a, ~ and 'Y subfamily were selected. In situ 
hybridization with CIO sense and anti-sense probe was also performed 
because the peculiarity of this C-C chemokine. 
All anti-sense probes showed the same pattern of hybridization, 
restricted to the areas in which the lymphangioma lesion was present. 
Among the lymphangioma cells the staining intensity was variable, as 
previously also described for Flt-4 and ICAM-I. That could be due to 
different expression levels or to a variable accessibility of the probes to the 
cellular transcripts. 
The liver parenchyma, cells of the diaphragm as well as vascular 
endothelial cells present in venules or in capillary structures resulted 
negative for hybridization with all the tested probes. 
The same positivity detected in lymphangioma cells, was also observed m 
lymphonodes (Fig. 23). This finding suggests that endothelial cells of 
lymphonodes (HEV, high endothelial venules), and lymphatic endothelial 
cells of the lymphangioma, share a simile profile of chemokine expression. 
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Figure 22. Analysis of chemokine expression in lymphangioma by In situ 
hybridization. 
Paraffin embedded sections of lymphangioma were hybridized with digoxigenin-
labelled sense and antisense RNA probes for Mig-I (CXC chemokine), JE (CC 
chemokine) and Lptn (C chemokine). Because of its remarcable expression observed 
in Northern blot analysis, in situ hybridization was performed also for CI0. The 
procedure was performed as indicated. All anti sense probes showed the same 
pattern of hybridization, restricted to the area in which lymphangioma is developed 
The same area was positive also for ICAM-I and Flt-4 (Fig. ISb and I7b,c). 
Figure 23. CIO expression in lymphnodes. 
In situ hybridization identification of elO mRNA expression in 
lymphnode. Paraffin embedded section hybridized with 
digoxigenin-labeUed sense RNA probes for C10. Arrows indicate 
areas in which the staining is particularly intense. 
As expected, control hybridizations with the corresponding sense 
RNA probes did not produce any detectable signal. 
Taken together all the results obtained led to the conclusion that the 
leukocytes recruitment observed in the tissue surrounding the 
lymphangioma lesion is due to a functional property of the lymphatic 
endothelial cells: the secretion of a large number of different chemokines. 
3.10 Chemotactic assay on different murine haemopoietic 
subpopulations 
Supported by the molecular data and from the evidence that the 
lymphangioma derived cells conditioned medium (LCM) displayed a 
remarkable chemoattractant activity on human PMN (Fig. 19), it was 
considered more appropriate to test activity of the LCM in a homologous 
system. In order to characterize the supernatant's activity, chemotactic 
assays were performed using as target cells purified haemopoietic 
subpopulations: PMN,lymphocytes and monocytes/macrophage cells. 
In addition, since we had observed an unexpected expression of the 
C10 chemokine in lymphangioma cells, previously described only as a 
product of bone marrow cells of the haemopoietic lineage (221, 222), we 
decided to investigate its activity. For this purpose, the eukaryotic expression 
vector pcDNA3 carrying the C10 complete coding sequence, was constructed 
and used to produce stable CHO transfectant clones expressing the ClO 
chemokine. Positive clones were identified by western blot analysis (Fig. 24) 
and their supernatants used in the chemotactic assays. 
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Figure 24. Western Immunoblot of CIO . 
Detection of CIa protein secreted by CHO cells transfected with 
PCDNA3/C10 cDNA. 50 III of differents supernatants of G418 
selected clones (n. 14, n. 15, n. 22, n. 27) were tested (lanes 4-6) and 
the amount of CIa was compared with the one of 50 III of 
lymphangioma conditioned medium. (L, lane 2). CHO untransfected 
cells supernatant (lane 1) and SP20 myeloma cell line conditioned 
medium (lane 7) were used as control. 
CIa chemokine (approx. 10kDa), was detected with a goat anti-
mouse CW. The reaction was developed by ECL. 
Since cells of murine origin are very weakly responsive to human IL-8 
chemotactic activity (276), medium containing 1% zymosan activated serum 
(ZAS) and recombinant murine MIP-1a. (25 ng/ml) were used as positive 
controls. Zymosan is a precipitate of yeast cell walls obtained by zymolyase 
enzyme digestion. The incubation of serum with yeast cell walls induces 
complement activation and cleavage of the third and the fifth component of 
complement generating C3a and C5a. C5a is the glycoprotein that accounts 
for the majority of biologically relevant chemotactic activity produced by 
complement activation (266). It was shown that C5a bind to a specific 
receptor on the surface of human neutrophils (49). This receptor is also a 
member of the G-coupled seven transmembrane receptor superfamily and 
C5a binding trigger a number of complex effects including cytoskeletal 
remodelling, shedding of selectin and up regulation of adhesion molecules, 
chemotaxis, granule secretion and activation of NADPH oxidase (105). 
Because of the similarities of C5a/ZAS activity with that of chemokine 
molecules and their receptors, it is widely used as a positive control in 
chemotactic assays. 
Chemotactic assay on peripheral blood PMN 
Fig. 25 shows the data obtained from five independent experiments in 
which chemotactic activity of LCM, or C10-transfected CHO cells 
supernatant and related controls were tested on a cell preparation composed 
by more than 95% of peripheral blood neutrophils. After 30 min. of 
incubation, approximately 20% of neutrophils stimulated by LCM was able 
to transmigrate into the lower chamber. When stimulated by ZAS the 
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Figure 25. Chemotactic assay on mouse peripheral blood PMN. 
PMN from mouse peripheral blood were purified on discontinuous Percoll gradient 
to >98% purity and used for chemotaxis with LCM (lymphangioma derived cells 
conditioned medium) and CIO in transwell chambers (pore size 1.2 !lm). ZAS 
(Zymosan activated serum) was used as a positive control. Unconditioned medium 
of lymphangioma (C) and the supernatant of untransfected CHO cells are the 
negative control for LCM and CIO respectively. Results of five independent 
experiments are shown. The efficency of migration is expressed as a percentage of 
input cells migrating after 30 min. at 37°C. The means for LCM and CIO were 
significantly different from the controls. (p<O.OOI). 
observed transmigration was 17% and was reduced to 6% in presence of the 
corresponding unconditioned medium. Thus, it appears evident that 
lymphangioma derived cells display a considerable chemoattractant activity 
also on these target cells. Although this data was expected because of the 
results obtained on human PMN, the chemotactic activity shown by ClO was 
somewhat unexpected. Approximately 17% of neutrophils stimulated by CIa 
was able to transmigrate, showing an efficiency comparable to the positive 
control ZAS. Chemotaxis by control untransfected CHO cells conditioned 
medium was 9%. 
This result is particularly interesting mainly because of the target cells 
involved. In fact, CIa has never been shown to be active on neutrophils and, 
in addition, most CC chemokines act preferentially on monocytes and 
lymphocytes and only rarely on neutrophils. From different studies, it 
emerges that most receptors recognize more than one chemokine, and 
several chemokines bind to more than one receptor, indicating that 
versatility and promiscuity characterize the chemokine system. At present 
CIa receptor has not yet been identified, and therefore CIa may bind to 
receptors expressed on the surface of neutrophils. Furthermore, the 
regulation of CIa expression differs from the one reported for other 
molecules of the same subfamily, thus suggesting a distinct role for this 
. molecule, even though its biological significance remains unclear. 
Chemotactic assay on peritoneal PMN 
The chemotactic activity of LCM and CIO was also evaluated on 
peritoneal neutrophils. These cells differ from their counterpart present in 
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Figure 26. Chemotactic assay on mouse peritoneal PMN . 
Polymorphonuclear cells from peritoneum were isolated from the peritoneal exudate 
of a thioglycolate peritoneal injected mice and separated on discontinuous Percoll 
gradient to >95% purity. Peritoneal PMN were tested for chemotaxis to LCM and 
CIO in transwell chambers (pore size 1.2 /lm). ZAS (Zymosan activated serum) was 
used as a positive control as described. Unconditioned medium of lymphangioma 
(C) and the supernatant of untransfected CHO cells are the negative control for 
LCM and CIO respectively. Histograms indicate the medians of four independent 
experiments. (p<O.OOl). 
peripheral blood because of their level of activation. The recruitment of 
neutrophils from blood vessels into the peritoneal area is induced by the 
presence of thioglycolate in the peritoneum. 
The figure 26 shows the results obtained on these PMN that are 
already primed to migrate. While the chemotactic activities of the LCM and 
negative control (19% and 7% respectively) were comparable to the ones 
obtained with peripheral blood PMN, the response obtained to ZAS 
stimulation was significantly higher on peritoneal PMN (78%). This 
difference is likely due to the fact that peritoneal neutrophils represent a 
selected, in vivo-stimulated subpopulation sensitive to the C5a chemotactic 
effect (276). Peritoneal neutrophils were practically not recruited by CIa (9% 
of migration vs. 4% of its control) suggesting that activation of PMN could 
be associated to loss of response to CIa possibly through down regulation of 
its receptor. 
Chemotactic assay on lymphocytes 
In order to evaluate the chemoattractant activity of LCM on murine 
lymphocytes, the assays were performed with an incubation time of 3h and 
using MIP-1a. as positive control. In general lymphocytes have a reduced 
migration capacity compared to neutrophils and monocytes. Differences of 
approximately 10% of migration are considered an accepted criteria to 
establish positivity in a migration assay of lymphocytes. As shown in Fig. 27, 
LCM and CIa were active when tested on a population composed by more 
than 95% of lymphocytes. More than 22% of cells incubated with LCM vs. 
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Figure 27. Chemotactic assay on mouse peripheral blood 
lymphocytes. 
Mouse lymphocytes were separated on discontinuous Percoll 
gradient to >95% purity and tested for chemotaxis to LCM and ClO 
in transwell chambers (pore size 1.2 ~m). MIP-la (25 ng/ml) was 
used as a positive control. Unconditioned medium of lymphangioma 
(C) and the supernatant of untransfected CHO cells are the negative 
control for LCM and C10 respectively. Histograms indicate the 
means of five independent experiments evaluated with the criteria 
previously described after 3hrs of incubation at 37°C. (p<O.OOl) . 
the 10% incubated with the unconditioned medium, was able to transmigrate 
whereas the MIP-l ex positive control showed an activity of only 17%. 
Similarly, 20% of lymphocytes were recruited in the presence of CIO 
compared to 13% of its control. These result indicated that chemokines for 
murine lymphocytes were produced by lymphangioma primary culture and 
also confirmed the previously reported activity of ClO on this haemopoietic 
subpopulation (222). 
Chemotactic assay on monoc:ytes I macrophage cell lineage 
Mice have a very low number of monocytes in the peripheral blood. 
In order to test the activity of LCM and CI0 on this subpopulation we used 
the murine monocytic-macrophage cell line J774, human monocytes and 
murine residential macrophage from the peritoneum. 
The results in Fig. 28 A showed no activity on the murine cell line (even after 
repeated independent preparation of LCM), while positive chemotaxis was 
obtained on human cells (Fig. 28 B). 
The murine peritoneal derived macrophages, which represent a more 
differentiated subpopulation of monocytes were also used as an alternative 
source of cells for the chemotactic assay. In Fig. 28 C are recorded the data 
obtained in assays performed with these cells. It is clear that LCM, was able 
to induce 60% of macrophage migration, comparable to the efficiency shown 
by the MIP-lex and ZAS positive controls (50% and 70% respectively). These 
results are indicative of the natural predisposition of activated peritoneal 
macrophage for migration. 
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Figure 28. Chemotactic assay on monocyte/macrophage cells. 
Chemotactic assays for cells belonging to the monocyte/macrophage lineage were 
performed in transwell chambers in which the pore size of the filter was 51lm and 
migration time was Ih at 37°C. As positive control for monocyte/macrophage 
chemotaxis was used ZAS (Fig. 25 A, 8, C), and MIP-la (25 ng/ml) (Fig. 25 C). All 
the reported data are the means of several experiments and by paired T-test was 
evaluated the significancy of the differences obtained. To establish, at the described 
condition, the chemotactic activity of LCM and of ClO on monocyte cells were used 
the murine monocytic cell line J774A.l (A), and human peripheral blood monocytes 
(8). In fig. 25 C are indicated the percentage of migration of resident peritoneal 
murine macrophages. 
CIa, differently from what was previously reported (23), seems lacking in 
chemoattractant effect on resident peritoneal macrophage. 
The data reported on the chemotaxis of LCM on the different murine 
subpopulations confirm our previous findings of the complex set of 
chemotactic molecules produced by the lymphatic endothelial cells. 
Furthermore, it is noteworthy our observation regarding the secretion of 
CIa by lymphatic endothelial cells as well as its chemoattractant activity on 
peripheral blood neutrophils. 
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Chapter 4 
DISCUSSION 
The understanding of the biology of angiogenesis is important for 
the comprehension of several normal and pathological processes, like 
haemostasis, thrombosis, atherosclerosis, inflammatory disorders and the 
neovascularization of tumours (92). The interest in angiogenesis, however, 
has been focused almost entirely on blood vessels and their endothelium. On 
the contrary, much less is known about the molecular biology and 
physiology of the lymphatic endothelium and the process of 
lymphangiogenesis in normal and pathological conditions. One of the 
reasons for this is the difficulty of establishing lymphatic endothelial cell 
cultures. Mouse lymphatic endothelial cells have been obtained from animals 
treated for long periods with the parasite Brugia malayi (160) or from the high 
endothelial venules (HEVs) of peripheral lymph nodes (25). Other reported 
examples are represented by the cultures of lymphatic endothelium isolated 
from bovine mesenteric lymphatic duct, from canine and human thoracic 
duct and from a patient with a massive cervicomediastinallymphangioma 
(30, 108, 138, 166). 
In humans, lymphangiomas are uncommon benign tumours, most 
frequently found in children in the head and neck and peritoneal regions, 
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and may also arise and enlarge rapidly in adulthood (170). The origin of this 
disordered lymphangiogenesis is still unclear and a congenital predisposition 
was suggested by different authors especially for the childhood forms (310). 
From clinical investigation and experimental evidences (59,216,46,51) arose 
the hypothesis of a possible link between the pathophysiological events of 
lymph stasis and disturbed lymphangiogenesis. Anatomical or functional 
lymphatic obstruction leads to a heightened intralymphatic transmural 
pressure which is transmitted to the endothelial cells as mechanical stress. 
This shear/strain effect, then, signals the lymphatic endothelial cells to 
release angiogenic mediators, similar to those produced by blood vascular 
endothelium (57, 195) inducing cell proliferation. The subsequent response 
may further enhance lymph formation despite a reduced lymphatic 
transport capacity. The accumulation of protein-rich edema fluid 
progressively disrupts attachments and adhesion of endothelial cells, 
promoting lymphatic remodelling and collateral formation. The angiogenic 
process reduces progressively the lymphatic drainage, involves release of 
growth factors and alterations of the extracellular matrix. All the process 
culminates in a dysplastic soft tissue overgrowth and occasionally in a highly 
aggressive lymphangiosarcoma. Nevertheless, also in cases of aggressive 
lymphangiosarcoma reported in humans, the frequency of metastasis 
establishment from this tumour is extremely low. 
Although experimental and spontaneous haemangiomas have been 
widely documented, this type of tumour has not been previously described 
in mice (124). Thus, the procedure we describe here is the first simple and 
rapid procedure for inducing lymphangiomas in mice with extremely high 
efficiency. The lymphangiomas obtained represent a unique and source of 
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lymphatic endothelial cells. We have shown that cells derived from this 
murine tumours can be expanded as primary cultures for several weeks 
leading to the spontaneous formation of vessel-like structures as was 
previously reported in lymphatic endothelial cell cultures from a human 
cervicomediastinal lymphangioma and in culture of cells of bovine thoracic 
duct origin (30, 168). This suggests that, although cells are derived from a 
tumour, they retain morphogenetic properties similar to normal cells. 1his 
possibly reflects the fact that the lymphangioma is a benign lesion with 
accumulation of cells of rather normal phenotype. Therefore the murine 
lymphangioma, could represent a convenient animal model to understand 
the basic mechanisms of lymphangiogenesis and functions of lymphatic 
endothelial cells as well as those related to disorders associated to these cells, 
such as lymphedema, angiofollicular hyperplasia, lymphangioma, 
lymphangiomyoma and malignant lymphangiosarcoma (309). 
The murine lesions obtained with injection of incomplete Freund's 
adjuvant, developed after few days in the peritoneal area, in a localization 
similar to what has been described for human acute lymphangioma to sis 
when it does not develop in the mediastinal area. The histological 
examination of the murine tumours revealed striking morphological and 
hystochemical similarities with the human counterpart (80). The lesion 
appears to be composed predominantly of a type of cells at different stages 
of differentiation, forming more compact areas (the parenchymatic parts of 
the tumour) and areas with more evident formation of lumen like structures. 
The lesion is not infiltrating the surrounding tissues and, as expected in this 
benign hyperproliferative disorders there is not involvement of endothelial 
cells of vascular origin as well as fibroblasts. The lesions does not shows any 
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presence of a basal lamina. Based on these observations it was hypothesized 
the lymphatic endothelial origin of the lesion. This hypothesis was supported 
by the following observations: a) the tumours had white colour, contrary to 
what is observed in haemangiomas, b) no red blood cells were seen inside 
most of the vessels, c) cells contained cytoplasmic vesicles of various sizes 
that seem to enlarge progressively and fuse with vesicles of adjacent cells to 
form the characteristic lumens, e) lumen like structures in which are evident 
the nuclei belonging to the different cells that are delineating the area, 
suggesting that these cells have the potential capacity to form vessels. 
The intraperitoneal administration of incomplete Freund's adjuvant 
has been widely used to induce myeloma in mice, to enhance an antibody 
response to antigens in vaccination protocols and to induce experimental 
immunological illnesses like arthritis and autoallergic disease (97, 236, 
239,293). However it has not been previously associated with the induction 
of lymphangiomas, in several publications lesions were reported to be 
caused by Freund's adjuvant, when administered at the doses here 
described. The lesions included polyarthritis, granulomatous proliferations in 
various organs and lipogranulomas of the peritoneum (128). These lesions, 
particularly the lipogranuloma, might actually correspond to what we have 
now characterized as lymphangioma. A single report has associated 
proliferation of the lymphatic endothelium in mice with the injection of 
Freund's adjuvant in footpad (156). 
The formation of the tumour is likely to be due to a direct 
stimulation of the peritoneal lymphatic vessels draining the oil adjuvant. This 
hypothesis was further supported by the observation that pristane, another 
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oil experimentally use in mice in order to favour the ascitic growth of 
myeloma and hybridoma cells (161) in the peritoneal cavity, was also 
effective in inducing the tumours. It may be possible that the density of these 
oils generate the lymph stasis that was suggested to be at the origin of the 
mechanism that leads to the disturbed lymphangiogenesis (46, 250). 
Moreover, the angiogenic potential of different lipids such as prostaglandins 
PGEl, PGE2, and certain uncharacterized polar lipids has also been described 
(93). Once induced, the lesions were permanent. Even 10 months after their 
induction, all animals showed tumours which were similar to those observed 
at the early stages, without any progressive development of the lesions. A 
neoplastic lesion was observed in the axillo lymph node in a single case over 
more than two hundred mice treated in this period. The benign nature of the 
lesion was also confirmed by the absence of cell proliferation and new 
tumours establishment when lymphangioma derived cells were injected in 
the peritoneal area of host syngenic mice. Certainly it will be extremely 
useful add extra experimental details (Le. bromodeoxyurodine studies to 
examine cell proliferation within the lesion; apoptosis studies to look at the 
extent of programmed cell death within the masses) in order to address the 
question if the described lymphatic lesions are tumours or represent 
phenomena of hyperplasia. Nevertheless, according to the definition that 
swelling or organ enlargement can also result from inflammation, 
physiological (Le. skeletal muscle) or pathological tissue adaptation and 
hypertrophy or hyperplasia are stimulus depending (287), and the lesions 
induced by Freund's adjuvant injections persist for long time after the 
initiating stimulus has been removed, this suggest that it may be correct 
think of the described lesions as a tumour of (lymphatic) endothelial cells. 
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In the work presented here we used different criteria to characterize 
the endothelial origin of the cells. We detected the expression of the 
endothelial markers PECAM-1/CD31, ICAM-1/CD54 and ICAM-2/CD102, 
as well as several endothelial cell growth factor receptors, like Flk-l, Flt-4, 
Tie-1 and Tie-2. 
PECAM-1/CD31 is a cell-cell adhesion molecule expressed at very 
early stage in the vasculogenesis process and is maintained also in mature 
vessel because of its involvement in the formation of inter-endothelial 
junctions, which are important for lumen formation, cell polarity and 
vascular permeability specially in vessel of vascular origin (162, 244). The 
heterorganic distribution of PECAM-1 displayed in lymphangioma is 
probably due to the fact that not only its expression in endothelial cells of 
lymphatic vessels is commonly weaker than in the vascular one (291), but 
also the lesion is composed by cells characterized by an active level of 
proliferation. 
In contrast, vWF was not expressed by the lymphangioma cells as 
shown by RT /PCR assay and no Weibel-Palade bodies were seen in electron 
microscopy. From data reported in literature the expression of vWF by the 
lymphatic endothelium is relatively controversial among different authors. 
Lymphatic endothelium of bovine thoracic duct has been shown to express 
vWF, but its expression became variable in human lymphoproliferative 
processes and it has also been shown to be absent in human lymph node 
HEVs (167, 168, 258). Probably, as widely described for the vascular 
counterpart, heterogeneity may be exhibited also by lymphatic endothelial 
cells. The other endothelial markers analysed, the integrins ligand ICAM-1 
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and ICAM-2, were both identified in lymphangioma lesion. The expression 
of ICAM-1 in endothelial cell is constitutively low, but its identification 
during the embryological process of vasculogenesis implies an early 
ontogeny for the endothelial signal transduction pathway necessary for 
leukocyte recruitment and suggests a developmental role for this member of 
the immunoglobulin superfamily (127). Moreover, ICAM-l induction on 
endothelium by inflammatory cytokines may increase cell-cell interaction 
and leukocytes extravasion at inflammatory sites, whereas constitutive 
expression of ICAM-2 may be important for leukocyte trafficking in tissues, 
as in lymphocyte recirculation (62,269). 
The detected co-expression in lymphangioma of Flk-l and its ligand 
VEGF, that is considered the most critical mediator of endothelial cell 
proliferation during embryonic vasculogenesis as well as in physiological 
and pathological angiogenesis in the adult (78, 87, 92) suggests an autocrine 
mechanism of growth stimulation as previously described for basic 
fibroblast growth factor (bFGF) (114). This co-expression is probably not 
sufficient to support by itself the rapid growth of the lesion, but supports the 
notion that tumour neovascularization as well as angioproliferative disease 
can be triggered by stimuli that induce endothelial cells to produce its own 
autocrine factor(s) (79, 231). Also the expression of VEGF-C, which is 
proposed as the molecule that may play a specialized role in the 
development of the lymphatic system (158), was investigated in 
lymphangioma, but without positive results. Probably VEGF-C and its 
receptor Flt-4 maintain the paracrine relationship that was suggested by the 
data obtained by embryological development studies. 
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Among all the endothelial specific receptors, Flt-4 is the most relevant 
one in the context of the lymphatic endothelium. Indeed, the Flt-4 tyrosine 
kinase receptor that has been identified at relatively early stage of mouse 
development (E.8.5) in the angioblast of head mesenchyme, in the cardinal 
vein and extraembryonally in the allantois, becomes restricted to developing 
lymphatic vessels during late stages of mouse embryogenesis (158). It has 
also been found in human cystic lymphangiomas and lymphangiomatosis 
(unpublished data of Taina Partanen and Kaipanen, 1995). The finding that 
Flt-4 is specifically expressed by adventitial cells is consistent with the view 
that also in mice this molecule represents a marker for lymphatic endothelial 
cells maintained in adult. We demonstrated by RT /PCR analysis, 
immunoblotting and in situ hybridization that the adjuvant-induced 
lymphangioma cells express Flt-4 and that the expression was also 
maintained in the in vitro propagated cell cultures producing the expected 
pattern of protein bands detected with the specific monoclonal antibody. In 
addition, the mice with a knock-in J3-galactosidase gene in the Flt-4 locus 
gave specific staining for the reporter gene in part of the tumour cells. 
Unfortunately, the Flt-4/lacZ mouse was not available in order to follow the 
Flt-4 expression in cell culture and the immunocyto-chemistry performed 
with the only available antibody on the explanted tissue or on cultured cells, 
probably for its technical characteristic, failed to give the expected results. 
These data should be extremely informative to address the question about 
the possible heterogeneity of the cell population forming the lesion and the 
level of non-endothelial cells contamination at the time of a more 
"established" primary culture. At present, the available data will not exclude 
the possibility of cellular heterogeneity, nevertheless a new criteria was 
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recently used in order to prove the nature of the cells forming the described 
lesion. Recently, the podoplanin, a novel 43-kDa membrane protein of 
podocytes, was reported by Breiteneder-Galeff et al. (35, 306) as a new 
marker for lymphatic endothelium. RT /PCR analysis for podoplanin 
expression on explanted tumour as well as on cultured cells mRNA was 
performed obtaining a positive results (data not show). At present, an anti 
mouse-podoplanin antibody for further investigation, is not available, but 
these preliminary data strengthen the hypothesis that the tumour contains 
abundant lymphatic endothelium and may be considered an extremely 
convenient model for further investigation of the biological properties of 
these cells. 
***** 
The salient feature of a variety of inflammatory conditions, such as 
infection, allergic disorders, autoimmune diseases, or ischemia/reperfusion 
injury is the association of infiltrating leukocytes. These extravasating 
leukocytes often contribute to the pathogenesis of the underlying disease. 
However, it should be appreciated that leukocyte recruitment is also critical 
for the host defence, leading to clearance of the inciting factor(s), i.e. 
infection. While at present the events of leukocyte trafficking may appear 
intuitive, it has taken more than one century of research to elucidate in part 
the molecular and cellular steps involved in the process of leukocytes 
migration. The maintenance of leukocyte recruitment during inflammation 
requires intercellular communication between infiltrating leukocytes and the 
endothelium, resident stromal and parenchyma cells. These events are 
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mediated via the generation of early response cytokines, e.g. IL-l , TNF-a, 
the expression of cell-surface adhesion molecules, and the production of 
chemotactic molecules, such as chemokines. Among the cell surface 
adhesion molecules, ICAM-l, which is expressed by activated endothelium 
and associates with the counter-receptor CDlla/CDI8 (Leukocyte function 
antigen-I, LFA-I) expressed on polymorphonuclear cells, plays an important 
role in the mechanism of leukocytes transmigration during acute 
inflammation (179, 265) and becomes upregulated by several molecules such 
as IL-l, TNF-a, LPS (256). ICAM-I up regulation promotes a dramatic 
increase in PMNs adhesion, with the participation of other accessory 
adhesion molecules of the selectin family like CD62E/E-Selectin and CD62P I 
P-Selectin. Thus, this adhesion molecule is an inducible endothelial marker 
and its expression level is related to a functional state of the cells. The finding 
that LEes express ICAM-I indicates that these cells represent an activated 
form of endothelium. 
Over the past ten years, an increasing number of chemokines have 
been identified as attractants of different types of blood leukocytes to sites of 
infection and inflammation. However the information obtained led to the 
knowledge that leukocyte recruitment during inflammation is only one of 
the different functions displayed by chemokines. It has been shown that 
chemokines are also involved in the inhibition and stimulation of blood 
vessel formation (11), in leukocytes maturation in the bone marrow (293) 
and in the regulation of physiological lymphocyte traffic (26, 206). The 
continuous recirculation of lymphocytes through the blood, tissues and 
lymphatics in an organized manner brings naive lymphocytes into the 
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lymph nodes, where they encounter antigen and are transformed into 
memory lymphocytes. 
Chemokines have been found to be secreted in response to a variety 
of factors by an array of cells including monocytes, alveolar macrophages, 
neutrophils, platelets, eosinophils, mast cells, T lymphocytes, NK cells, 
keratinocytes, mesangial cells, epithelial cells, fibroblast, smooth muscle cells, 
mesothelial and endothelial cells. The production of chemokines by both 
immune and non immune cells support the contention that chemokines play 
important roles in different processes. In order to investigate the 
chemokines biological effects, regulation of expression, and possible role in 
disease, different in vitro and in vivo approaches have been developed. In 
particular, the production of chemokine by endothelial cells in response to 
several stimuli (e.g. inflammatory cytokines, hypoxia, bacterial LPS) (185) is 
well documented. Most of the information, however, is related to the 
expression of chemokines by cells of vascular origin, while limited 
documentation exists in relation to lymphatic endothelial cells. This 
difference reflects the absence of suitable models for the isolation and the 
culture maintenance of endothelial cells of lymphatic vessels as well as the 
only relatively recent discovering of appropriate markers in order to 
characterize unequivocally these cells. The main model systems available for 
LEes consist on the use of high endothelial venules (HEV) and Peyer's 
patches cells which are rather heterogeneous in their composition and 
represent a very distinct stages of differentiation. The model of LEes isolated 
from lymphangioma that we describe offers the possibility of addressing 
other questions related to LEes functions. One of these is the production of 
chemokines. We became interested in this problem because of an 
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observation arising from the histological analysis of the lesion. It was evident 
the presence of leukocytes, mainly neutrophils, in the area of the tissue 
neighbouring the lymphangioma. In all the histological sections analyzed no 
infiltration of the recruited leukocytes into the lesion or any sign of necrosis 
in the area in which leukocytes accumulated was observed. These facts 
indicated that the lymphangioma was producing chemokines and suggested 
that it could represent a model for the characterization of the profile of 
chemokine expression by the lymphatic endothelium. 
From the preliminary screening performed by RT /PCR analysis, 
arose the evidence that different chemokines were expressed by lymphatic 
endothelial cells forming the lymphangioma. With the exception of the MIP-
la, MIP-l~ and MIP-ly chemokines, known to be secreted mainly by the 
monocyte/macrophage cell lineage (311, 323), expression of the other 
chemokines, belonging to all chemokine subfamilies (CXC, CC and C) was 
detected. This finding suggests that the possible contamination by 
monocyte/macrophage cell lineage in the lesion induced by Freund's 
adjuvant could be relatively low, or that these cells, if present, are not 
activated, but this hypothesis seems rather improbable. 
Among the detected molecules, the expression of CXC chemokines IP-IO, 
MIG-I, BCL, and of CC chemokines Exodus/6Ckine, IE, CIO and the C 
chemokine Lymphotactin was confirmed by Northern blot and in situ 
hybridization. Some of these are novel chemokine (e.g. BCL, Exodus-2, 
6Ckine) that are selectively expressed in secondary lymphoid organs (spleen, 
lymph nodes, thymus, Peyer's patches), attract preferentially T or B 
lymphocytes and could playa role in lymphocytes homing and maturation. 
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Interestingly the expression of KC, a CXC chemokine that together 
with MIP-2a and MIP-2~ (218, 283, 311), performs the functions of IL-8 in 
mice, was not confirmed by Northern blot suggesting a very low level of 
expression. A similar situation was observed for RANTES which is a CC 
chemokine with potent chemotactic and activating properties for basophils, 
eosinophils and NK cells (141, 169). This chemokine is also known to have 
HIV-suppressive effect and to synergize with MIP-1a, MIP-1~ in the 
suppression of HIV (53). Interestingly, these chemokines exhibit 30% amino 
acid sequence identity to the two genes product of Kaposi's Sarcoma 
associated herpes virus (KSHV or HHV -8) the etiological agent of the 
angioproliferative malignant lesion associated with HIV infection. At present 
there are no functional data on the viral CC chemokines, which could be 
involved in the chemoattraction of haemopoietic cells into KS lesions (197, 
207». 
For all the other chemokines tested the demonstration of their 
expression in lymphangioma was established by in situ hybridization. The 
data obtained suggests a complex profile of chemokine expression by LECs 
which may include other members of the chemokine family that were not 
investigated here. In addition it is also possible that LECs express specific 
chemoattractant molecules. Previous reports have led to the general 
consensus that members of the CXC subfamily are chemotactic to 
polymorphonuclear leukocytes (PMN) including neutrophils, eosinophils an 
basophils, while members of the CC subfamily are generally chemotactic to 
mononuclear cells such as monocytes and lymphocytes (217). However 
some exceptions to this paradigm have been described in both CXC and CC 
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subfamilies Ke, IP-lO and JE, RANTES respectively (13). The C chemokine 
Lymphotactin is chemotactic exclusively for T lymphocytes (149). 
Among all the chemokines expressed by LECs, we found members 
of all three families. Although some of chemokines function on PMN, a large 
number of chemokines produced by LECs are specifically active on different 
populations of lymphocytes (Leptn, Exodus/6Ckine, BCL, IP-10, MIG). 
A particular case is that of C10 chemokine. This molecule was 
previously described as a chemoattractant exclusively produced by murine 
bone marrow derived cells or resident peritoneal macrophages cells after 
stimulation with GM-CSF, IL-3 or IL-4 (221,222). The biological significance 
of this chemokine is still unknown. Even though structurally it belongs to the 
CC chemokine subfamily, it has been reported to be active on mouse 
peritoneal exudate cells (PECs ) as well as on human peripheral blood 
mononuclear cells (23,,222). 
Our results show that C10 was actively produced by LECs representing one 
of the chemokines with the highest level of expression and suggesting that it 
could play a relevant role in the chemoattractant activity of LECs for 
lymphocytes. Surprisingly, we observed that C10 was active on peripheral 
blood neutrophils, while it was not on peritoneal neutrophils, and residential 
peritoneal macrophages, two types of cells with high migrating capacity, 
differently from what has been reported (23) . 
C10 differs from other CC chemokines RANTES, MIP-la., and JE in 
its regulation. Although these chemokines are all induced by LPS treatment 
of bone marrow-derived macrophages and/ or resident peritoneal 
macrophages, C10 stimulation by LPS was never observed. Conversely, C10 
is strongly induced by IL-3 and GM-CSF in both macrophage populations, 
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whereas the induction of RANTES, MIP-1a., and JE not only is weaker, but 
also restricted to bone marrow-derived macrophages. Finally, IL-4 strongly 
induces C10 in a dose-dependent manner, while is ineffective for the other 
chemokines. IL-4 has been reported to display many effects that enhance 
macrophage function (6, 272, 292) and others that appear to be anti-
inflammatory, such as suppression of interleukins production, down-
regulation of macrophage cytotoxic and microbicidal activities, reduction of 
Fey receptor expression (122,282, 134). The selective induction of C10 by IL-4 
suggests that this chemokine plays a role in mediating these functions, in 
particular it might promote the cell-cell interactions involved in the 
development of humoral responses (222). Supporting this hypothesis, it has 
been reported that CIO is chemotactic for both B cells and CD4+T helper 
cells, although details in the mechanism of action are still limited by the fact 
that the receptor of this chemokine is not yet known, neither the human 
homolog has been identified. In other cases, such as the murine CCF18 and 
the human MIP-1 delta (121, 301) differences in cell target activity and 
regulation have been described in spite of their homology and similar 
structural features. 
As mentioned above, recruitment of PMNs was observed in the 
region surrounding the lesion. We found that two chemokines GE and MIP-
2) of well documented activity on these cells were expressed by LECs and 
could in part explain our observation. An interesting question is related to 
the absence of necrosis of the recruited cells as well as the absence of 
infiltration into the tumour. From studies on inflammation processes it is 
well known that neutrophils, or more generally granulocytes, leave the 
blood stream to migrate into the tissue following appropriate inflammatory 
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stimuli, but once arrived to the injured area, they perform their biological 
functions and die in situ. There is not a clear explanation for the absence of 
necrosis that we observed, neither for the strong recruitment of PMNs in the 
area proximal to the lesion, since these cells are not able to recirculate. One 
possibility is that other yet unidentified molecules produced by the LEC can 
control this process or that the observed event is not related to an 
inflammatory process. 
Among the chemokine expressed by LECs we identified several 
molecules with known activity on lymphocytes. This was paralleled by the 
migration assay performed with the supernatant of LECs. Those results are 
particularly relevant because they represent the first direct evidence that 
lymphatic endothelial cells participate in the control of lymphocytes 
trafficking and homing, a process not only important for the establishment 
of specific defence in pathological situations, but also for the maintenance of 
the immunological homeostasis in a organism, through the production of 
chemokines. Following the hypothesis that the LECs obtained from the 
experimental induced lymphangioma, are able to secrete chemokines of 
various type, new questions arise. For instance, it is not yet clear which of 
the chemokines are actually expressed by normal LEC and which is the 
relative importance of each one of them in lymphocytes trafficking within 
lymphatic vessels. Some indications come from the results obtained with 
lymphangioma derived cells spontaneously transformed and kept in culture 
for prolonged time and from primary culture obtained from tumours 
harboured in mice for period longer than six months. When those cells were 
analyzed by RT /PCR, they were still positive for the expression of some 
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chemokines active on lymphocytes such as IP-IO, lptn and MIG (data not 
shown). 
The possibility to identify new chemokines restricted to lymphatic 
endothelium expression would be extremely helpful for the understanding 
of the physiological recirculation of lymphocytes, and could provide new 
lymphatic endothelium specific markers. 
Independently from the evidences reported by the presented data, 
many shadow areas remain to be enlightened and questions to be 
addressed. Up to date several attempts were done to immortalize a cell line 
Flt-4 and podoplanin positive starting from LECs. So far these attempts were 
unsuccessful, but recently a spontaneous transformed clone, already tested 
by RT /PCR analysis, seems to present these characteristics. The opportunity 
to work with a homogeneous lymphatic endothelial cells line, will be 
extremely promising to answer many of the questions arising from present 
thesis, first of all the possibility of demonstrate the origin of the chemokines 
produced, as well as to determine which stimuli induce chemokines 
expression and their relative/reciprocal regulation. 
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